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ABSTRACT 
 
COMPARISON OF TUMOR SHRINKAGE AND CUMULATIVE DOSE 
DISTRIBUTION FOR LUNG CANCERS 
Publication No.________ 
Yi Pei Chen, B.S. 
Supervisory Professor: Laurence E. Court, Ph.D. 
 
Background: The physical characteristic of protons is that they deliver most of their 
radiation dose to the target volume and deliver no dose to the normal tissue distal to the 
tumor. Previously, numerous studies have shown unique advantages of proton therapy 
over intensity-modulated radiation therapy (IMRT) in conforming dose to the tumor and 
sparing dose to the surrounding normal tissues and the critical structures in many 
clinical sites. However, proton therapy is known to be more sensitive to treatment 
uncertainties such as inter- and intra-fractional variations in patient anatomy. To date, 
no study has clearly demonstrated the effectiveness of proton therapy compared with 
the conventional IMRT under the consideration of both respiratory motion and tumor 
shrinkage in non-small cell lung cancer (NSCLC) patients.  
 
Purpose:  This thesis investigated two questions for establishing a clinically relevant 
comparison of the two different modalities (IMRT and proton therapy). The first 
question was whether or not there are any differences in tumor shrinkage between 
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patients randomized to IMRT versus passively scattered proton therapy (PSPT). Tumor 
shrinkage is considered a standard measure of radiation therapy response that has been 
widely used to gauge a short-term progression of radiation therapy. The second question 
was whether or not there are any differences between the planned dose and 5D dose 
under the influence of inter- and intra-fractional variations in the patient anatomy for 
both modalities.  
 
Methods: A total of 45 patients (25 IMRT patients and 20 PSPT patients) were used to 
quantify the tumor shrinkage in terms of the change of the primary gross tumor volume 
(GTVp).  All patients were randomized to receive either IMRT or PSPT for NSCLC.  
Treatment planning goals were identical for both groups. All patients received 5 to 8 
weekly repeated 4-dimensional computed tomography (4DCT) scans during the course 
of radiation treatments. The original GTVp contours were propagated to T50 of weekly 
4DCT images using deformable image registration and their absolute volumes were 
measured. Statistical analysis was performed to compare the distribution of tumor 
shrinkage between the two population groups. In order to investigate the difference 
between the planned dose and the 5D dose with consideration of both breathing motion 
and anatomical change, we re-calculated new dose distributions at every phase of the 
breathing cycle for all available weekly 4DCT data sets which resulted 50 to 80 
individual dose calculations for each of the 7 patients presented in this thesis. The 
newly calculated dose distributions were then deformed and accumulated to T50 of the 
planning 4DCT for comparison with the planned dose distribution. 
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Results: At the end of the treatment, both IMRT and PSPT groups showed mean tumor 
volume reductions of 23.6% (  19.2%) and 20.9% (  17.0 %) respectively. Moreover, 
the mean difference in tumor shrinkage between two groups is 3% along with the 
corresponding 95% confidence interval, [-8%, 14%].  The rate of tumor shrinkage was 
highly correlated with the initial tumor volume size.  For the planning dose and 5D dose 
comparison study, all 7 patients showed a mean difference of 1 % in terms of target 
coverage for both IMRT and PSPT treatment plans.      
 
Conclusions:  The results of the tumor shrinkage investigation showed no statistically 
significant difference in tumor shrinkage between the IMRT and PSPT patients, and the 
tumor shrinkage between the two modalities is similar based on the 95% confidence 
interval.  From the pilot study of comparing the planned dose with the 5D dose, we 
found the difference to be only 1%.  Overall impression of the two modalities in terms 
of  treatment response as measured by the tumor shrinkage and 5D dose under the 
influence of anatomical change that were designed under the same protocol (i.e. 
randomized trial) showed similar result. 
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Chapter 1 
Introduction 
 
1.1 Background 
Introduction to IMRT and Proton Therapy 
 
One of the major goals in radiation therapy is the local control of tumor. It is a 
well-known fact that higher dose to the tumor will increase success of local control. 
However, delivering high dose to a tumor is restricted by the radiation tolerance of 
organs at risks (OAR) or normal tissue surrounding the tumor volume. The field of 
radiation oncology and, in particular, its method of delivering external beam radiation 
have changed rapidly including new technologies in linear accelerator and computerized 
treatment planning over the last two decades.  After the first introduction of 3-
dimentional imaging technology such as computed-tomography (CT) in the early 1980s, 
the development of virtual simulation using a computerized treatment planning system 
(TPS) quickly followed (Bucci, Bevan et al. 2005). With these advancements in hand, 
many hospitals adopted 3-dimensional conformal radiation therapy (3DCRT) technique 
in which the dose distribution from each radiation beam is shaped to fit the contour of a 
given target in beam’s eye view based on a computerized patient image data set.  By 
employing many such beams, 3DCRT was able to significantly reduce the amount of 
dose to the surrounding normal tissues, thereby allowing dose escalation to the tumor 
for a better therapeutic outcome. Now, 3DCRT is considered the conventional 
technique for hospitals in many developed countries.  Despite the huge improvement of 
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going from what was essentially a 2D plan radiation therapy to 3DCRT, it was very 
difficult or impossible to spare critical structures that push into or partially surround a 
target (Galvin, Ezzell et al. 2004). In order to further escalate dose to the target, a more 
conformal dose distribution was necessary. The idea of modulating the intensity of the 
incoming radiation beam using moving leaves in a motorized fashion attached to a 
gantry was first conceived by Dr. Takahashi in early 1960s (Takahashi and Matsuda 
1960). Thirty years later, researchers started developing multileaf collimators (MLC) to 
create multiple collimated fields for existing 3DCRT units. This process was then fully 
automated and integrated to the TPS to deliver conformal radiation efficiently. (Brahme 
1988; Galvin, Smith et al. 1992; Brewster, Mohan et al. 1995).  
 
 
Figure 1.1  A schematic of MLC with its leaf position conforming to a target volume in beam’s 
eye view (left) and an example of a working MLC that is attached to a IMRT unit by Varian 
SmartBeamTM (right) 
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While the MLC technology was being developed, another important 
development known as inverse-planning was invented (Brahme 1988; Bortfeld, 
Burkelbach et al. 1990).  The concept of inverse-planning is that a user indicates the 
desired goals of radiation therapy in terms of target coverage or dose constraint to 
nearby critical structures and computer tries to optimize the plan by determining the 
best treatment parameters. Traditionally, for 3DCRT, treatment plans have been 
designed using forward-planning. In forward- planning, the treatment planner must 
specify the number of fields, gantry angles, and collimator settings first, and then 
calculates the resultant dose distribution. With inverse-planning, it is possible to let a 
computer optimize any beam parameters of treatment planner’s choice including the 
intensity of radiation beam that can be controlled with use of MLC. The integration of 
3DCRT with MLC and inverse-planning became the basis of intensity modulated 
radiation therapy (IMRT).  In a typical IMRT treatment planning, treatment planners 
can specify dosimetric goals with respect to the target and surrounding OARs. After 
preselecting basic plan parameters such as number of beams and gantry angles, an 
inverse-planning capable TPS will optimize the intensity of radiation beams and relative 
radiation beam weight to meet the planning objectives by manipulating collimator jaws 
and MLC leaf positions. The MLC leaves can move in and out of the open field in order 
to shape the dose profile and modulate transmission of the open beam, essentially 
allowing non-uniform beam intensities for each beam to be delivered (Webb et al 
2003). Previously, many researchers and clinicians reported advantages of IMRT over 
3DCRT both in treatment planning studies and clinical studies (Hall and Wuu 2003; 
Luxton, Hancock et al. 2004; Vlachaki, Teslow et al. 2005; Yom, Liao et al. 2007). The 
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advantages of IMRT over 3DCRT in terms of its ability to shape the dose to a target, 
spare dose to surrounding tissues, and specify dose objectives were so significant that it 
quickly became the state of art of external beam radiation therapy today.  
In recent years, there has been increasing interests in treating cancer using high 
energy protons. The concept of treating cancer using high energy protons was first 
introduced by Wilson in 1946 (Wilson 1946 Wilson, RR. 1946. Radiological uses of 
fast protons.  Radiology 47:487). The chief advantage of proton over photon is that it 
stops, giving the radiation beam a finite range in the patient body so that one can spare 
normal tissue distal to the tumor volume completely whereas for photon it is impossible 
to completely spare normal tissue directly along the direction of radiation beam. The 
depth dose curve of proton, which is often denoted as the Bragg curve, shows another 
important advantage of proton radiation compares to a typical depth dose curve 
obtained by photon radiation. When proton radiation interacts with a medium, it 
deposits relatively low dose at the entrance region but releases most of its energy at the 
end of its range before it falls to zero abruptly (see figure 1.2). However, a typical 
Bragg peak width is in the order of a few millimeters and it is not large enough to cover 
a typical tumor size. Therefore, many Bragg peaks are combined in order to generate a 
spread-out Bragg peak (SOBP). The width of an SOBP can be made to extend across 
any given target volume. However, in creating the SOBP, the low entrance dose given 
by the single Bragg peak must also be summed which increases entrance dose. 
Typically, this entrance dose is still on the order of 20% less than the dose given to the 
tumor volume for photon beam. Therefore, the advantage of proton over photon is still 
retained (See figure 1.2).  However, due to the huge cost and size of facility required to 
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build a proton therapy center, the initial development of proton therapy was limited to 
high-energy physics facilities (Tobias, Lawrence et al. 1958).  With the advancement of 
technology in accelerator physics, some vendors started to provide hospital based 
proton therapy facilities in the early 1990s (Slater, Miller et al. 1991).  Since the 
beginning of 2000, the number of hospital based proton facilities increased dramatically 
and as of now there are 33 proton facilities in operation world-wide and 10 proton 
facilities in the United States. The number of hospital based proton facilities is expected 
to grow more in the next few years with many centers currently under construction or in 
the planning state. Even though, the theoretical advantage of proton therapy over the 
conventional external beam radiotherapy using photons was noted earlier. Since the 
birth of proton therapy in the early 1960’s and its popularization into the early 2000, 
much technological advancements have occurred on the side of photon radiation 
therapy including IMRT that raises a question on whether or not proton therapy can 
demonstrate clinical advantage over IMRT. 
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Figure 1.2 The Bragg peaks of different initial energy of protons (top) and an example of SOBP 
that is created by adding 6 different Bragg peaks of different energy and intensity. (Courtesy of 
Dr. Wayne D. Newhauser, Louisiana State University, USA) 
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Comparing IMRT vs. Proton Therapy 
 
In recent years, the debate between IMRT vs. proton has been a hot topic in the 
radiation oncology community. As the number of proton therapy centers increases, 
there is a concern about whether or not the clinical advantage of proton therapy is well 
justified over the cost of building and maintaining proton centers (Brada, Pijls-
Johannesma et al. 2007; Konski, Speier et al. 2007).  Although the physical 
characteristic of proton’s low entrance dose and no exit dose give clear theoretical 
advantages over IMRT, clinically feasible plans are not simple to be delivered.  The 
actual clinical treatment plan is complicated with many parameters that can be vastly 
different between IMRT and proton plans. For example, a number of beam angles tend 
to be greater for IMRT which can potentially improve dose conformity in higher dose 
region. Also, treatment planning parameters (e.g. margins) can vary significantly 
between the two modalities that can potentially affect the final dose distribution.  There 
have been many articles written in the past years comparing the dosimetric difference 
between IMRT and proton therapy in various treatment sites. A search of published 
manuscripts with both IMRT and proton as keywords on scopus.com resulted in a total 
number of 223 published scientific journals with increasing number of publications 
every year. Most of these publications are based purely on dosimetric studies that 
compared the dose distribution of IMRT and proton therapy plans but lack of clinical 
assessments such as patient follow-up morbidity, toxicity, or survival data. In 2007, 
Olsen et al conducted a comprehensive systematic literature review to survey the 
clinical effectiveness of proton therapy (Olsen, Bruland et al. 2007; Goitein and Cox 
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2008).  In their study which looked at 54 different publications concluded that the 
evidence on clinical efficacy of proton therapy so far has relied on non-controlled 
studies that are poorly designed for the purpose of comparing IMRT and proton therapy.  
 
1.2  NIH P01 Randomized Clinical Trial 
 
Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths in the 
United States. (Chang, Zhang et al. 2006)  Despite the recent advancement in cancer 
treatment, clinical outcome of NSCLC remains poor partly due to the difficulty in 
escalating dose to tumor in the presence of highly radiation sensitive critical structures 
such as lung, spinal cord, heart, and esophagus.  With conventional radiotherapy, its 5 
years survival rate is only 10-30% (Dosoretz, Katin et al. 1992). Although IMRT could 
deliver higher dose to the tumor, dose constraint to the surrounding healthy lung tissue 
has been the greatest barrier for further dose escalation. Recently, a few dosimetric 
studies demonstrated the advantage of proton therapy in lung cancer treatment over 
IMRT that can potentially allow further dose escalation to achieve better clinical 
outcome for lung cancer patient (Zhang, Li et al. 2009; Chang, Zhang et al. 2006). 
However, the lack of a proper randomized clinical trial to show the evidence of proton 
therapy’s superiority over IMRT prompted many discussion in the radiation oncology 
community (Halperin 2000; Glasziou, Chalmers et al. 2007; Glimelius and Montelius 
2007; Lodge, Pijls-Johannesma et al. 2007; Olsen, Bruland et al. 2007; Goitein and Cox 
2008; Macbeth 2008).  With recent developments and popularization of proton therapy 
in the United States, increasing interest to conduct a randomized trial prompted the 
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national institute of health (NIH) funded P01 randomized clinical trial of various tumor 
types and locations including NSCLC by the collaboration between Massachusetts 
General Hospital in Boston, Massachusetts and University of Texas M.D. Anderson 
Cancer Center in Houston, Texas. At the time of writing this thesis, this trial is still 
ongoing. 
 In this randomized clinical trial, patients are treated either with IMRT or 
passively scattered proton therapy (PSPT).  This trial would not only answer whether or 
not PSPT is better than IMRT, but it would also help rectify the current challenges 
involved in lung cancer radiation therapy.  As an example, in this thesis work, as one of 
many projects involved in the randomized clinical,  will demonstrate a method of 
estimating delivered dose to a patient that takes into account of both breathing motion 
and anatomical change over the course of treatment for more accurate assessment of 
NSCLC therapy. All patient datasets (e.g. images, treatment plans, and etc.) related to 
this thesis work are sampled from the larger patient cohort of the randomized clinical 
trial. Only the patients with stage II-IIIB NSCLC who were enrolled for concurrent 
chemotherapy were eligible for this trial. Once the patient is enrolled, two radiation 
therapy plans were created, one for IMRT and one for PSPT, by following the identical 
planning goals and objectives (i.e. target coverage and dose constraint to critical 
structures). Only those patients with the plans that met the specific dose objectives for 
both IMRT and PSPT were allowed to enter the randomized trial. If either IMRT or 
PSPT plan did not meet the specified dose objectives, whichever plan that met the dose 
objectives was selected for treatment and the patient was removed from the trial. The 
process of creating a treatment plan is as follow:  First, four-dimensional computed 
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tomography (4DCT) simulation is acquired for treatment planning purpose.  The details 
of 4DCT simulation are discussed later in this chapter. Tumor motion is then evaluated 
using the 4DCT images at different breathing phases (Vedam  et al 2002, Rietzel et al 
2005). If the tumor motion is greater than 1cm, an active motion management technique 
such as voluntary breath-hold treatment is provided (Vedam, Keall et al. 2001; Ford, 
Mageras et al. 2002).  However, in this study, those patients are excluded in order to 
minimize bias introduced by the motion management techniques. In order to assess 
anatomical change and its influence on dose distribution, each patient receives weekly 
4DCTs throughout the course of treatment. For each weekly 4DCT, images are 
imported into the Pinnacle3 treatment planning system (TPS) for contouring target and 
critical structures. For this study, every contour was delineated on the T50 phase of 
4DCT because our analysis will be performed on this particular phase. T50 phase was 
chosen because the anatomy of patient is most stable during the end of exhale of 
breathing cycle ((Balter, Lam et al. 1998)). The target volumes are created by first 
delineating the gross tumor volume (GTV). The contour of GTV was expanded to form 
clinical target volume (CTV) to include surrounding microscopic diseases that are 
generally not visible on CT images. The contour of GTV on T50 phase is then deformed 
to other phases of breathing cycle to form the motion encompassing gross tumor 
volume called integrated-GTV (IGTV). The IGTV is further expanded to internal target 
volume (ITV) again to include microscopic disease and the ITV is then further 
expanded to planning target volume (PTV) isotropically using 5-7mm margins to 
compensate for possible setup error. For critical structures, brachial plexus, esophagus, 
liver, total lung, spinal cord and heart are contoured on the T50 phase image. Once 
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every contour is defined, treatment plans for both IMRT and PSPT are created based on 
the same predefined dosimetric objectives. The primary treatment planning goal is to 
deliver 74Gy to 95% of the planning target volume (PTV) while achieving various dose 
constraints to different critical structures as listed in table 1.1.   
 
Table 1.1 Tolerance limits for critical structures 
 
Critical Structures Dose Limits [Gy] 
PTV (Planning Target 
Volume) 
> 99% volume receiving  > 95% of 74Gy 
Brachial plexus Minimum dose to 2% highest dose volume < 60 Gy 
Esophagus 1/3 volume < 65 Gy; 
2/3 volume < 55 Gy 
Liver Mean dose to liver < 25 Gy; 
1/3 liver < 35 Gy 
Total Lung  Mean lung dose < 20 Gy; 
V20 < 37% of volume; 
Mean lung dose < 22Gy and V20 up to 40% are acceptable 
as minor deviations 
Spinal Cord Maximum dose to 2% highest dose volume < 50 Gy 
Heart 1/3 volume < 60 Gy; 
2/3 volume < 45 Gy; 
Mean heart dose < 30 Gy 
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For IMRT plan, 5 to 7 beam angles are typically used to cover the target area 
with prescribed dose while only 2 to 4 beam angles are used for PSPT plan. Once beam 
angles are chosen, the dose distributions for each plan are calculated and target 
coverage as well as tolerance limits to all critical structures are checked. A patient is 
randomized between IMRT and PSPT only if both IMRT and PSPT treatment plans 
meet these criteria. Otherwise, the patient is removed from the randomized trial and 
whichever plan provided better target coverage and normal tissue sparing is selected for 
treatment. The overall flow chart of NIH P01 randomized clinical trial is shown in 
figure 1.3 with details explained in the following sections. 
 
Figure 1.3 Overall flow chart for treatment planning process: Each patient is given a 4DCT 
simulation that is used to create both IMRT (x-plan) and PSPT plans (p-plan). Then, the patient 
is randomized between IMRT and PSPT only if both plans meet the given criteria.  After 
randomization, the patient receives weekly 4DCT for treatment review to see if adaptive 
planning is necessary. (Courtesy of Dr. Lei Dong, M.D. Anderson Cancer Center, Houston, TX) 
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Four-dimensional Computed Tomography (4DCT) 
 
In radiation therapy of thoracic site such as NSCLC cases, breathing motion 
introduces multiple problems such as image artifacts, inaccurate assessment of tumor 
position and its motion extent, and dose calculation (Keall, Mageras et al. 2006). In 
order to resolve the problems, 4DCT was developed to capture CT images of breathing 
motion at specified intervals which allowed accurate target delineation, motion 
assessment, and motion mitigating techniques such as breath-hold and gating treatment 
(Keall, Mageras et al. 2006).  In order to collect and sort the CT images at a certain 
interval, each CT images must be time-stamped while patient’s breathing cycle is 
tracked and recorded. The time stamping of CT images is done by the CT scanner 
machine during its data acquisition. The patient’s breathing cycle can be tracked and 
recorded by using either internal or external markers. Most commonly used external 
markers are abdominal displacement or the flux of inhaled and exhaled volume of air 
respectively.  The abdominal displacement can be tracked and recorded through infrared 
reflective plastic box placed on the patient’s anterior abdominal surface and the flux of 
inhaled and exhaled volume of air can be traced using a spirometer. Internal marker can 
be patient anatomy itself which can be traced through real-time imaging such as 
ultrasound or fluoroscopy or it could be surgically implanted internal fiducial markers 
(Keall, Mageras et al. 2006). At M.D. Anderson Cancer Center, the acquisition of 
4DCT follows a previous method reported by Pan et al. closely (Pan, Lee et al. 2004). 
In their method, CT images of patient are continuously acquired over a period greater 
than the normal breathing cycle (i.e. 15 images per any given table position for 3 to 4 
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seconds) using cine-mode that is available on multi-slice Discovery GE CT scanner 
(General Electric Medical Systems, Waukesha, Wisconsin) while recording external 
respiratory signal given by the Real-Time Position Management (RPM) respiratory 
gating system (Varian Medical Systems, Palo Alto, CA). Once both images and external 
motion signal are acquired, the sorting of images at different axial location according to 
their common breathing cycle time be binned together. The full cycle of breathing 
motion from RPM signal is divided into 10 bins that are equally spaced in time. Then, 
3DCT images set corresponding to a single phase is derived by collecting images that 
have closest time-stamped to the selected phase at every table position. This process can 
be repeated for other phases to generate ten 3DCT image sets that represent different 
phase of breathing cycle. A simplified illustration of phase binning process is depicted 
in figure 1.4 (Pan, Lee et al. 2004). 
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Figure 1.4 An illustration of scanning and image reconstruction of phase binned 4DCT: The 
sinusoidal wave represents breathing cycle (i.e. external signal from RPM). The dots on the 
wave represent individual phases. [Permission to publish this figure was obtained from Tinsu 
Pan, Ting-Yim Lee, Eike Rietzel, and George T. Y. Chen, Medical Physics, 2004, 31: 333-340] 
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During our 4DCT simulations, patients are immobilized with a T-bar handgrip, 
wing boards, and vacuum immobilization devices (Medical Solutions, Kalona, Indiana) 
in order to minimize inconsistency in patient setup. Each scan will be acquired using 50 
cm field-of-view (FOV) with 2.5mm slice spacing. After the 4DCT simulation, extent 
of tumor motion can be measured (i.e. centroid motion of tumor mass) and based on the 
contours of GTV at individual phases, motion encompassing target volume (i.e. IGTV 
and ITV) can be defined.  For patients exhibiting motion greater than 1cm, motion 
mitigating technique can be recommended based on assessment of 4DCT. Furthermore, 
in order to compensate for the breathing motion during dose calculation step, an 
averaged CT image set is derived by summing images of each phases of 4DCT. 
Because the averaged CT partially contains geometrical information of every phase, 
dose calculation based on this blurred image of patient anatomy can help mitigate 
dosimetric error caused by breathing motion (Admiraal, Schuring et al. 2008). 
 
 Deformable Image Registration for contour propagation 
 
The purpose of specific aim I is to track tumor shrinkage throughout the 
treatment course using weekly 4DCT.  Manual contouring is not feasible by the 
physicians in terms of labor cost and efficiency.  Moreover, each patient receives 5 – 8 
weekly 4DCT data sets, so it is a time-consuming process to delineate contours on 
every single week.  Therefore, we are going to use a technique named deformable 
image registration that can automate this process efficiently.  Deformable image 
registration is a technique of registering two images through spatial mapping of 
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corresponding locations using computer algorithm (Cachier and Pennec 2000).  It 
allows two objects to be different in terms of size, orientation, and shape be deformed 
with respect to each other in two different images.  The application of deformable 
image registration to radiation oncology has been extended to but not limited to auto 
segmentation of patient anatomy, contour propagation, and dose accumulation (Brock, 
McShan et al. 2003; Liang and Yan 2003).  In this thesis work, we use deformable 
image registration to propagate contours to different sets of images.  For example, 
contours at any given phase of 4DCT will be propagated to different phases of 4DCT.  
Also, the contours drawn on the simulation 4DCT will be propagated to the weekly 
4DCTs. All of deformable image registration algorithms establish deformation vector 
field that contains displacement vector of corresponding points in 3D space. Figure 1.5 
illustrates the concept of deformable image registration.  
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Figure 1.5 Illustration of deformable image registration between two images: Two points 
(orange dot) in different images are spatially correlated under the transformation that deforms 
fixed image to moving image under “assumed” action force. (Courtesy of Dr. Lei Dong, M.D. 
Anderson Cancer Center, Houston, TX) 
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In this thesis work, we employ an in-house developed deformable image 
registration software called CT-Assisted Targeting for Radiation Therapy (CAT) that 
uses ‘demons’ algorithm.  In demons’ algorithm, every pixel on the reference image is 
assumed to be under action force (i.e. local ‘demon’ is assumed to apply ‘invisible’ 
force) that moves pixel to the location given by the moving image (i.e. target image). 
The computer software seeks to solve this demon’s force at every pixel by employing 
optical flow formula as follow:  
 
where  is the gradient of static image and  is the internal force originating from the 
static image. The   term is the differential force of the interaction between the 
static and moving images where m and s are the CT numbers (Thirion 1998; Wang, 
Dong et al. 2005) .The detail of how above optical flow solution is actually solved in 
computer is beyond the scope of a master’s thesis but can be found in Wang’s paper 
(Wang, Dong et al. 2005).   Demons algorithm is based on the assumption that the 
corresponding pair of points on different images share the same image intensity values 
(i.e. gray scale value on CT images) thus the accuracy of registration relies heavily on 
similarity of intensity histogram of the images (Wang, Dong et al. 2005). In this thesis, 
all of deformable image registrations are performed to register CT to CT images (i.e. 
same modality) of the identical patients (i.e. phase to phase or week to week 
registration) and therefore the image intensity histograms of both target and reference 
images are assumed to be well-matched. Moreover, before deformable (non-rigid) 
image registration is perform, rigid registration is performed first by align two images 
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into the same location using bony structures (Wang, Dong et al. 2005). The accurate 
validation of any deformable image registration is difficult because the ground truth in 
real clinical problem is difficult to establish.  However, limited scope of validation 
study by using mathematical or physical phantoms, as well as human assessment can be 
performed to boost the confidence in the registration algorithm in clinical setting. 
Previously, Wang et al.  showed the validation of the demons’ algorithm as 
implemented in the CAT software by applying mathematical transformation to real 
patient images and also on the physically deformable phantom (Wang, Dong et al. 
2005). The result of their study provided an estimate of 2 mm accuracy to our current 
deformable image registration software. 
 
Deformable Image Registration for Dose Accumulation 
 
As mentioned in the previous section, deformable image registration produces 
deformation vector field which contains spatial relationship between two corresponding 
points on different sets of images.  Not only this information can be used to propagate 
contours but also it can be used to combine dose values given to any tissue element on 
different sets of CT images. Because dose distribution is calculated based on the input 
CT images, the dose distribution is necessarily associated only with the anatomy given 
by that CT image.  Thus, when a new dose distribution is calculated on a different CT 
image set (i.e. different phase of 4DCT or weekly 4DCT), one cannot simply add the 
two dose distributions in space coordinate to obtain accumulated dose. Rather, spatial 
location of a tissue element must be followed from one CT images set to another CT 
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images using deformation vector fields to accumulate dose to that element (Brock, 
McShan et al. 2003). Notice that for this thesis, in order to compare the planned dose vs. 
delivered dose, we chose T50 of 4DCT simulation as our reference.  Although we can 
choose any other phase as our reference phase, T50 is chosen since it already has 
contours on it and it is the most stable phase as mentioned before.  The application of 
deformable image registration for dose accumulation has been used in adaptive 
radiotherapy (Schaly, Kempe et al. 2004).  However, it should be noted that dose 
accumulation via deformable image registration is not well established in clinical 
setting due to the difficulty of interpretation of such result. Unlike contour propagation, 
dose accumulation is more complicated by the fact that the “deformed” dose 
distribution is much harder to visually assess its accuracy compare to the propagated 
contour because dose distribution does not necessarily needs to conform to well-
defined, visually detectable boundary of anatomy or tissues (Bender, Hardcastle et al.)  
Currently, active research is underway to develop accurate method of accessing 
accumulated dose through deformable image registration. For example, recently 
published work by Yeo et al showed that the accuracy of dose accumulation can be 
measured using a full 3D physically deformable gel dosimeter phantom (Yeo, Taylor et 
al.).  In their study, they were able to deliver dose to the radiosensitive gel phantom 
before and after physical deformation and compared the ‘measured’ dose distribution 
against ‘calculated’ accumulated dose distribution using many commercially available 
deformable image registration software. In their study, they showed the accuracy of 
accumulated dose calculated using ‘demons’ based deformable image registration to be 
up to 34% using 3% dose and 3mm distance gamma criterion: 34% of the phantom’s 
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measure accumulated dose were agreement with calculated dose within 3mm and 3%. 
However, it should be noted that their study is limited to the use of homogenous gel 
phantom whereas real patient anatomy is more heterogeneous and therefore the 
deformation introduced to the gel phantom may not mimic the realistic deformation that 
can occur inside the patient including disappearing of tissues and organ swelling. 
 
1.3 Statement of the Problem 
 
The goal of this thesis work is to improve cancer treatment for patients 
undergoing NSCLC radiation therapy.  We can achieve this goal by questioning our 
current techniques.  The first question is whether or not the difference in the 
uncertainties associated with both modalities would cause a difference in tumor 
shrinkage.  It is a well-known fact that there are numerous uncertainties associated with 
our inability to deliver the intended dose to a target (Paganetti et al. 2012). A few major 
contributors are setup uncertainty, internal motion, changes in patient anatomy, and 
inaccuracies in imaging and simulation data. Previously, researchers reported that some 
of these uncertainties can result in greater effects for protons than photons 
2011(Engelsman, DeLaney et al. ; Unkelbach, Chan et al. 2007; Lomax 2008; Lomax 
2008).  In particular, range uncertainties in proton therapy, primarily due to the error in 
estimated stopping powers of patient anatomy and the uncertainty in estimated relative 
biological effectiveness (RBE), are unique to proton therapy (Moyers, Sardesai et 
al.2010 ; Yang, Zhu et al. ; Paganetti, Niemierko et al. 2002).  This noted difference 
leads to the question of whether or not the intended prescription dose to the tumor is 
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being delivered for both modalities. If there is indeed a significant difference in 
delivered dose between the two modalities, then we might be able to see the difference 
in terms of tumor shrinkage. The second question is how much difference is there 
between the delivered dose and planned dose for both modalities and how changes in 
patient anatomy will affect the delivered dose distribution. Changes in anatomy can 
cause changes in the dose distribution, which can be more significant for proton therapy 
than IMRT (Zhang, Dong et al. 2007; Albertini, Bolsi et al. 2008; Hui, Zhang et al. 
2008). However, there are subtle differences in the treatment planning process for both 
modalities, such as different margins and different techniques involved in accounting 
for the uncertainties, which is hard to judge the sensitivity without direct assessment of 
the delivered dose.  For the purpose of this thesis, from now on, we will refer delivered 
dose as “5D” dose such that 5D dose is the cumulative dose distribution from all 10 
phases and from all available weekly 4DCT data sets for one patient.    
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1.4 Hypothesis and Specific Aims 
1.4.1 Hypotheses 
Hypothesis 1: We hypothesized that there is a statistically significant difference in 
tumor shrinkage between lung cancer patients treated with IMRT and those treated with 
PSPT. 
Hypothesis 2: We hypothesized that there is a statistically significant difference 
between planned and 5D dose in both IMRT and PSPT plans of the lung cancer 
patients. 
1.4.2 Specific Aims 
Specific Aim 1: To compare tumor shrinkage between Intensity Modulated Radiation 
Therapy (IMRT) and Passively Scattered Proton Therapy (PSPT) using weekly 4DCT 
and deformable image registration 
Specific Aim 2: To establish a method of estimating the 5D dose of both IMRT and 
PSPT using weekly 4DCT and deformable image registration and to perform a pilot 
study of comparing planned dose to 5D dose for both modalities 
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Chapter 2 
 
 Comparison of Tumor Shrinkage in IMRT and PSPT 
of Lung Cancer 
 
Specific Aim I: To compare tumor shrinkage in Intensity Modulated Radiation 
Therapy (IMRT) and Passively Scattered Proton Therapy (PSPT) using weekly 
4DCT and deformable image registration* 
 
*This study was presented at 2011 Joint AAPM/COMP meeting as a short oral 
presentation. 
2.1 Introduction 
 
Patients who receive radiation therapy show significant change in tumor shape 
and volume as the tumor responses to radiation or concurrent chemotherapy (Barker, 
Garden et al. 2004; Hansen, Bucci et al. 2006; O'Daniel, Garden et al. 2007).  As an 
effort to correctly identify treatment response, a treatment response criterion called 
Response Evaluation Criteria in Solid Tumors (RECIST) was introduced by the 
European Organization for Research and Treatment of Cancer (EORTC) and National 
Cancer Institutes of the United States and Canada (Therasse et al 2000). According to 
RECIST, tumor shrinkage is considered a standard measure of therapy response.  In 
RECIST, it is recommended that the size of lesions (i.e. sum of the longest diameter of 
all lesions) should be calculated and reported. Based on the evaluation of tumor size, it 
provides response criteria ranging from complete response (i.e. disappearance of all 
lesions), partial response (i.e. at least 30% decrease), stable disease (i.e. no significant 
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change), and progressive disease (i.e. at least 20% increase). With the innovation and 
improvement of computed tomography (CT), it is now a routine practice to use CT to 
measure tumor volume at the simulation and to track tumor shrinkage throughout the 
treatment course if repeated CT is available. Currently, there is a randomized clinical 
trial of intensity-modulated radiotherapy (IMRT) vs. passively scattered proton therapy 
(PSPT) for non-small cell lung cancer patients (NSCLC) at M.D. Anderson Cancer 
Center. The details of this randomized trial were discussed in chapter 1.  Although the 
end goal of this randomized clinical trial is to cross-compare the clinical outcome in 
long term survival rate of the patients who were treated either with IMRT or PSPT, 
understanding the tumor shrinkage in both modalities can provide us with immediate 
assessment of therapy response.  
In the design of this randomized clinical trial, it was assumed that the same 
prescription dose, 74 Gy, was delivered to the clinical target volume (CTV) of patients 
treated with IMRT and PSPT. However, there are uncertainties in the beam delivery 
process such that the CTV coverage shown in the nominal plan (i.e. plan at the time of 
simulation) may not be what was actually delivered. It has been argued before, that 
there are unique aspects of proton therapy which makes it more sensitive to the error 
caused by patient setup, internal motion, anatomical deformation, and range uncertainty 
(Lomax 2008; Lomax 2008). If our ability to deliver the prescribed dose to the CTV is 
worse in PSPT than IMRT, we would expect to see the difference in tumor shrinkage in 
patients treated with PSPT.   
Another unique uncertainty in proton therapy is the relative biological 
effectiveness (RBE). Previously, researchers have found a wide range of RBE values 
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both in vivo and in vitro studies using protons (Gerweck and Kozin 1999; Paganetti, 
Niemierko et al. 2002).  It is now believed that the true RBE value can vary for different 
linear energy transfer (LET), dose, and tissue type (Wilkens and Oelfke 2004; Chen and 
Ahmad 2012). However, the true RBE is difficult to determine in practice as it requires 
a map of LET which in turn requires a Monte-Carlo simulation that is difficult and time 
consuming for practical purpose (Wilkens and Oelfke 2004). Furthermore, even after 
the LET distribution is known, matching the correct RBE values that varies for different 
tissue types is still a challenge (Paganetti, Niemierko et al. 2002). For these reasons, 
most proton therapy centers including  M. D. Anderson Cancer Center have adopted a 
constant RBE value of 1.1 for prescribing and reporting proton dose (Paganetti, 
Niemierko et al. 2002). If this assumption of the RBE value for PSPT is significantly 
off, then we would expect to see a difference in tumor shrinkage caused by the 
difference in the magnitude of tumor response when compare with IMRT patients. 
In summary, the main goal of the specific aim 1 is to compare the tumor 
shrinkage in non-small cell lung cancer patients who underwent randomized clinical 
trial between two different treatment modalities (protons vs. photons).  It gives a unique 
opportunity to assess tumor response to proton or photon therapy because patients are 
randomized to receive the same dose prescription.  
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2.2 Methods and Materials 
2.2.1 Patient Selection 
A total of 45 patients (25 IMRT and 20 PSPT patients) who had completed their 
treatment courses were included in our analysis. Patients with an initial tumor size less 
than 5 cc were excluded from this study due to limitation of in-house deformable image 
registration, CT-Assisted Targeting For Radiation Therapy - CATV3.0.  Our power 
analysis revealed that in order to detect 10% difference in tumor shrinkage between the 
two modalities with desired power of 0.8 and under the assumption that the data is 
normally distributed with standard deviation of 10% would require 16 samples from 
each group. The patients included in this study were the subset of the patient population 
who were enrolled in the NIH P01 randomized clinical trial between IMRT and PSPT 
with concurrent chemotherapy. So far, this on-going clinical trial has accrued 150 
locally advanced NSCLC patients (stage II-IIIb) who were randomized to receive either 
photon (IMRT) or proton (PSPT) therapy. The details of the randomized trial were 
discussed in chapter 1 and only a short description that is relevant to this chapter is 
given here. The protocol includes several dose levels (74Gy, 66Gy, and 60Gy) as shown 
in figure 2.1.  The primary objective was to deliver 74 Gy to CTV but if the adequate 
target coverage levels are not met at the highest dose level (74 Gy), then the next lower 
dose level (66Gy or 60 Gy) is assigned.  If both IMRT and PSPT plans meet the criteria 
for adequate target coverage level which is defined as the 95% of planning target 
volume (PTV) receiving 74 Gy to CTV and if the mean lung dose is less than 22Gy and 
V20 is less than 40%, then patients are randomly assigned to either IMRT or  PSPT.  
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For our study, only patients who were randomized to the 74 Gy dose level (i.e. 2 Gy per 
fraction, a total of 37 fractions) were selected.  
 
Figure 2.1 Three different dose levels for the lung protocol. At first, for all candidate 
patients, a treatment plan is designed with intention of delivering 74 Gy to CTV while 
meeting the dose objectives for other organs at risk for each IMRT and PSPT. If either 
plan can’t achieve 74 Gy to CTV without compromising the dose objectives, the 
prescription is lower to 66 Gy. If the dose objectives are still not met, it is further lower 
to 60 Gy. Once the appropriate dose level for CTV is determined, patient is randomized 
between IMRT and PSPT.  In this study, only the patients who received 74 Gy were 
analyzed to reduce variability in patient population.  
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2.2.2 Contouring and Deformable Image Registration 
 
Weekly four-dimension computed tomography (4DCT) images were acquired 
for all patients in this protocol. In order to measure tumor shrinkage, we kept track of 
the volume of primary gross tumor volume (GTVp) using weekly 4DCT data sets 
throughout the treatment course. Previous study showed that GTV was the most reliable 
parameter to predict disease control probability (Strongin, Yovino et al.).  Initially, the 
GTVp was contoured by the board certified physicians on the end-of-expiration phase 
(T50) of the planning 4DCT data sets. All manual contours were performed using a 
Pinnacle3 treatment planning system (Phillips Medical Systems, Andover, MA).  
However, re-contouring the GTVp on every weekly 4DCT posed great demand from 
clinical staffs. Therefore, we used the deformable image registration to propagate the 
original GTVp drawn by the physicians on the newly acquired weekly 4DCT data sets.  
First, the original planning CT images and contours were exported from Pinnacle3 
treatment planning system and imported into CT-Assisted Targeting For Radiation 
Therapy (CATV3.0) which is an in-house developed deformable image registration based 
on demons algorithms.  The utility of this deformable image registration software were 
validated elsewhere (Wang, Dong et al. 2005) and the details of the deformable image 
registration were discussed in chapter 1.  Then, the original GTVp from T50 of 4DCT 
simulation was deformed to T50 of all available weekly 4DCT data sets.  The changes 
in volumes were measured and recorded for all weeks.  Figure 2.2 shows the interface 
of CATV3.0.  software and the “Daily” windows show the newly acquired CT image set 
(i.e. T50 of weekly 4DCT) and the “Ref” window shows the original CT image set (i.e. 
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T50 of simulation 4DCT). The red box region is first defined in order to preselect area 
which deformable image registration should occur and the deformation vector fields are 
computed.  Once the deformable image registration is completed, the newly generated 
contours were visually inspected to make sure there are no obvious discrepancies (e.g. 
contours were in the wrong region of interest or discontinuity in contours).  Notice that I 
have generated every new contour myself.  Finally, we compared the individual tumor 
shrinkage, group average tumor shrinkage, tumor volume at the end of treatment, week 
by week tumor shrinkage, and rate of volume change. 
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Figure 2.2 The graphical user interface of the CAT.  In this user-friendly environment 
where both “Daily” and “Reference” images are cross compared.  The red box region 
represents the pre-selected area where deformable image registration occurs.  The newly 
deformed GTVp contours (bottom left) were visually assessed for its overall integrity 
by comparing it to the original contour (bottom right ).   
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2.3  Results 
Individual Tumor Shrinkage 
The individual tumor shrinkage curves for all patients from each group are 
shown in figure 2.3. Each deformed volume was normalized to its initial volume 
measured at the first week CT data set. It should be noted that that the “Days after start 
of treatment (i.e. day 0)” to the time of weekly 4DCT scan date varies slightly among 
the patients; not all patients received weekly 4DCT scan on the same day of the week. 
The comprehensive data that includes the volume change of GTVp for all patients of all 
weeks are shown in table 2.1 and 2.2 .  Out of 25 IMRT patients, 3 patients showed no 
sign of tumor shrinkage (i.e. greater or equal GTVp volume at the end of treatment 
course).  For PSPT patients, 1 out of 20 patients showed no sign of tumor shrinkage.   
 
Figure 2.3 The GTVp volume change over elapsed treatment day for both IMRT 
(red) and PSPT (blue) patients 
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Table 2.1 The absolute and relative volumes of deformed GTVp of each week for IMRT patients. The weekly GTVp volumes were 
normalized to the GTVp volume at week 1.  
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 
Patient No. [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] 
1 14 100 14 100 13 93 13 93 12 87 12 86 12 88   
2 298 100 217 73 194 65 223 75 201 67 178 60 178 60 181 61 
3 9 100 8 91 8 91 7 85 7 85 8 87 7 78 7 86 
4 106 100 99 93 92 86 91 86 91 85 90 85 89 84 87 82 
5 55 100 55 100 54 98 58 106 59 107 59 107 55 101 58 105 
6 202 100 137 68 120 60 118 58 103 51 109 54 103 51   
7 10 100 9 93 10 97 10 101 9 87 9 88 9 86   
8 283 100 264 93 248 88 238 84 228 81 223 79 221 78   
9 18 100 18 104 19 106 18 103 18 105 18 105     
10 14 100 15 102 14 96 15 103 16 108 15 106 14 97   
11 40 100 46 114 47 116 45 112 41 101 40 98 43 106 43 106 
12 30 100 27 91 23 76 19 63 20 67 24 78 20 66 21 71 
13 53 100 50 94 50 93 50 94 49 93 48 91 50 93   
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Table 2.1 Continued. 
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 
Patient No. [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] 
14 255 100 230 90 214 84 183 72 166 65 155 61 149 58   
15 520 100 421 81 309 59 256 49 227 44 224 43 220 42 213 41 
16 54 100 51 95 48 89 47 87 49 92 45 84 42 78 42 78 
17 197 100 183 93 157 80 142 72 120 61 115 58 108 55   
18 15 100 15 100 15 99 15 100 15 96 15 96     
19 146 100 107 73 98 67 86 59 94 65 95 65     
20 56 100 49 87 36 65 34 61 32 56       
21 64 100 57 89 36 56 30 47 32 49       
22 46 100 41 89 40 86 42 90 40 85 39 85     
23 32 100 31 97 30 94 26 80 25 77 24 76     
24 49 100 45 92 39 79 33 68 29 60 28 58 27 56   
25 63 100 64 101 58 91 58 92 59 93 57 90 55 87   
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Table 2.2 The absolute and relative volume of deformed GTVp of each week for PSPT patients. The weekly GTVp volumes were 
normalized to the GTVp volume at week 1 because radiation treatment has started by then.  
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 
Patient No. [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] 
1 5 100 6 108 5 99 5 97 5 98 5 101 5 104   
2 13 100 13 99 12 90 11 85 12 89 11 83     
3 198 100 208 105 201 101 212 107 224 113 207 104 200 101 196 99 
4 622 100 621 100 559 90 549 88 452 73 403 65 373 60 326 52 
5 32 100 32 101 30 94 24 76 23 71 23 72 23 73 27 84 
6 104 100 109 105 106 102 101 97 93 90 84 81 92 89 88 85 
7 7 100 7 98 7 91 6 88 6 83 6 83 6 79   
8 150 100 136 91 124 83 115 77 113 75 119 79 134 89 93 62 
9 582 100 564 97 559 96 545 94 511 88 498 85 500 86   
10 335 100 355 106 296 88 305 92 278 83 256 77 235 70 224 67 
11 48 100 46 95 45 92 43 90 46 95 46 95 45 94   
12 184 100 179 98 176 96 179 97 181 99 181 99     
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Table 2.2 Continued. 
 
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 
Patient No. [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] [cc] [%] 
13 9 100 8 89 7 87 8 96 7 87 7 80 6 73   
14 41 100 40 99 38 94 37 92 39 95 36 88     
15 228 100 204 90 215 94 177 76 166 73 176 77 175 77   
16 64 100 70 109 72 112 62 96 68 106 72 112 62 97   
17 39 100 38 97 36 93 37 96 35 89 32 83 31 79   
18 152 100 195 128 158 104 152 100 141 93 124 81 121 80 99 65 
19 149 100 131 88 120 81 111 75 100 67 110 74     
20 465 100 418 90 316 68 237 51 204 44 186 10 169 36   
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Group Average Tumor Shrinkage 
In order to minimize potential bias that can be introduced by daily time 
difference, we interpolated the weekly measured data given in table 2.1 and 2.2 to 
generate daily tumor shrinkage by using linear piece-wise interpolations between two 
consecutive weeks: in between two weekly measurements, we assigned daily 
progression of tumor volume change by fitting a line between the two end points (See 
Appendix A:  Table A.1 and Table A.2).  Figure 2.4 shows the mean change of GTVp 
for each group.  The dashed lines representing the ±1st standard deviation of the average 
are also plotted to indicate the population variation.   
 
 
Figure 2.4 The population average of volume change of GTVp (solid line) and the 
standard deviation (dashed line) over elapsed treatment day for both IMRT (blue) and 
PSPT (red) patients is shown. 
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Comparison of Tumor Volume at the End of Treatment  
 
Tumor volume at the end of treatment was used as the end point for this study to 
detect any clinical significant difference in tumor shrinkage between IMRT and PSPT.  
Table 2.3 shows the normalized GTVp volume and amount of shrinkage for all patients.  
Based on the tumor volume measured at the last 4DCT data sets, we found that on 
average, GTVp was reduced by 24% (  19%) and 21% (  17 %) for IMRT and PSPT 
respectively.  The mean difference in tumor shrinkage between IMRT and PSPT was 
calculated to be 3% and its corresponding 95% confidence interval was calculated to be 
[-8%, 14%].   
The distribution of the “end-of-study” tumor volume measurements are 
compared as box plots in figure 2.5. In order to determine if the observed difference in 
tumor shrinkage is statistically significant, we used the last recorded volume of GTVp 
for all patients from the two groups and performed the unpaired t-test with Welch’s 
correction using the statistical package software R (GNU general public open source 
code).  We found that there is no statistical difference in mean tumor shrinkage between 
the two arms (p-value 0.65 > 0.05).  In this study, our null hypothesis was that the mean 
tumor shrinkages between the two modalities are the same.  According to this statistical 
test, based on our sampled means for two group (i.e. 24% and 21% for IMRT and PSPT 
respectively) and under the 95 % confidence interval, we cannot reject the null 
hypothesis, meaning that there is no evidence that the tumor shrinkage between the two 
groups is different. 
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Table 2.3 Tumor volumes measured at the last 4DCT for IMRT and PSPT patients 
 
 IMRT 
patient 
No. 
Normalized 
Volume* 
Tumor 
Shrinkage 
PSPT 
patient 
No. 
Normalized 
Volume* 
Tumor 
Shrinkage 
 1 0.88 0.12 1 1.04 -0.04 
 2 0.61 0.39 2 0.83 0.17 
 3 0.86 0.14 3 0.99 0.01 
 4 0.82 0.18 4 0.52 0.48 
 5 1.05 -0.05 5 0.84 0.16 
 6 0.51 0.49 6 0.85 0.15 
 7 0.86 0.14 7 0.79 0.21 
 8 0.78 0.22 8 0.62 0.38 
 9 1.05 -0.05 9 0.86 0.14 
 10 0.97 0.03 10 0.67 0.33 
 11 1.06 -0.06 11 0.94 0.06 
 12 0.71 0.29 12 0.99 0.01 
 13 0.93 0.07 13 0.73 0.27 
 14 0.58 0.42 14 0.88 0.12 
 15 0.41 0.59 15 0.77 0.23 
 16 0.78 0.22 16 0.97 0.03 
 17 0.55 0.45 17 0.79 0.21 
 18 0.96 0.04 18 0.65 0.35 
 19 0.65 0.35 19 0.74 0.26 
 20 0.56 0.44 20 0.36 0.64 
 21 0.49 0.51    
 22 0.85 0.15    
 23 0.76 0.24    
 24 0.56 0.44    
 25 0.87 0.13    
mean   0.24   0.21 
STD   0.19   0.17 
*Normalized Volume = Volume divided by baseline volume 
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Figure 2.5 The boxplot comparison of tumor volume measured at the “end-of-study” between 
IMRT and PSPT. (The midline = mean, box = lower and upper quartile, and the outer lines = 
10% and 90%) 
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Week by week Tumor shrinkage comparison between IMRT and PSPT 
 
Since the last recording date of tumor volume was different for different 
patients, there may be a bias in comparing the “end-of-study” data points. We have 
performed the same statistical analysis based on the tumor shrinkage measured at the 
end of each week separately.  The result of week by week tumor shrinkage comparison 
is summarized in table 2.4. Despite the fact that the mean tumor shrinkage of IMRT 
group was lower than PSPT group in all weekly comparisons, these differences were 
not statistically significant.  
 
Table 2.4 Week by week Tumor shrinkage comparison between IMRT and PSPT  
 
 
 
Mean Difference 
(IMRT - PSPT) 
P-Value 
(Welch’s t-test)  
95% Confidence Intervals 
of the Mean Difference 
End of Week1 -2.5% 0.21 [-6.6%, 1.6%] 
End of Week2 -4.2% 0.16 [-10.1%, 1.7%] 
End of Week3 -3.6% 0.34 [-11.2%, 3.9%] 
End of Week4 -3.9% 0.40 [-13.2%, 5.4%] 
End of Week5 -4.0% 0.42 [-13.9%, 5.9%] 
End of Week6 -5.9% 0.29 [-16.9%, 5.2%] 
End of Week7 -1.9% 0.80 [-17.2%, 13.3%] 
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Rate of volume change for IMRT and PSPT patients 
Another interesting factor of radiation therapy is the rate of volume change or 
how fast tumor responds to the radiation therapy.  The rate of volume change was 
computed from the slope of observed data for each patient as shown in table 2.5 and 2.6 
and negative values indicated tumors were getting smaller. Figure 2.6 shows the linear 
relationship between initial volume and the rate of volume change for both IMRT and 
PSPT patients.  Red color represents IMRT patients and blue color represents PSPT 
patients.  The slope is the same, 0.07, for both IMRT and PSPT patients. 
Table 2.5 Rate of volume change for IMRT patients 
Patient No. Rate of volume change [cc/week] 
1 -0.35 
2 -12.89 
3 -0.19 
4 -2.20 
5 0.44 
6 -13.17 
7 -0.21 
8 -10.27 
9 0.13 
10 0.07 
11 -0.31 
12 -1.15 
13 -0.53 
14 -18.47 
15 -40.94 
16 -1.60 
17 15.72 
18 -0.15 
19 -8.66 
20 -6.36 
21 -9.27 
22 -1.31 
23 -1.79 
24 -3.81 
25 -1.33 
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Table 2.6 Rate of volume change for PSPT patients 
Patient No. Rate of volume change [cc/week] 
1 -0.006 
2 -0.45 
3 -0.35 
4 -46.11 
5 -1.22 
6 -6.21 
7 -0.26 
8 -5.12 
9 -15.28 
10 -18.07 
11 -0.30 
12 -0.13 
13 -0.30 
14 -0.85 
15 -9.37 
16 -0.24 
17 -1.34 
18 -10.14 
19 -8.51 
20 -52.28 
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Figure 2.6 Linear regression fitted Lines for GTV of IMRT (red) and PSPT groups 
(blue).  
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2.4 Discussion 
In this study, we analyzed gross tumor volume changes in patients who received 
IMRT and PSPT radiation therapy.  The tumor volumes drawn by the physicians at the 
beginning of the radiation therapy were followed through using deformable image 
registration to propagate the original contour to the newly acquired weekly 4DCT 
images throughout the entire treatment course.  Based on the mean difference in tumor 
shrinkage between IMRT and PSPT, 3%, along with the corresponding 95% confidence 
interval, [-8%, 14%], we can conclude that the tumor shrinkage is similar between two 
treatment modalities.  Moreover, the result of this study showed that there is no 
statistically difference for both modalities indicating that the same prescription dose (74 
Gy) is delivered to the target for both modalities regardless of associated uncertainties 
in beam delivery process. This could be an indication that our current treatment 
planning procedure for PSPT is at least as robust as the conventional IMRT.  During our 
analysis of tumor shrinkage, it was noted that an important contributing factor in large 
tumor volume reduction was the initial volume of tumor as shown in figure 2.7.  We 
found that the rate of volume change is highly correlated with the initial volumes as 
indicated by the Pearson correlation coefficient (Pearson correlation coefficient =0.94 
and 0.86 for IMRT and PSPT respectively).  It was observed that the larger the initial 
tumor volume, the faster the volume shrunk. The relationship between the rates of 
volume change vs. initial volume of tumor was the same for both IMRT and PSPT. 
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2.5 Conclusion 
Majority of IMRT and PSPT patients showed tumor shrinkages as they 
responded to the radiation treatment.  Despite the fundamental difference in photon and 
proton radiation therapy, we found no statistically significant difference in tumor 
shrinkage between lung cancer patients randomized to receive IMRT or PSPT to 74 Gy.  
The average tumor shrinkage for patients receiving IMRT and PSPT was similar.  
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Chapter 3 
Comparison of Dose Distributions in IMRT and PSPT 
of Lung Cancer 
Specific Aim II: To establish a method of estimating the 5D dose of both IMRT 
and PSPT plans using weekly 4DCT and deformable image registration and to 
perform a pilot study of comparing planned dose to 5D dose for both modalities 
 
*This study was presented at 2012 AAPM Annual Meeting as a poster. 
 
3.1 Introduction 
 
 Radiation therapy involves many steps such as treatment simulation, tumor 
delineation, treatment planning, patient setup, and finally, the delivery of the external 
radiation beam. Each of these steps comes with uncertainties that can influence the 
delivery of dose to a patient (Cho et al., 2007; Lomax, 2008a, b; Zhu et al., 2008; 
Zhang et al., 2012; Yang et al., 2012). Some of these uncertainties can be addressed 
during the treatment planning process and their impacts on the anticipated delivered 
dose can be assessed before the treatment begins. For example, in IMRT, patient set up 
error can be accounted by using a planning target volume (PTV) which is an expansion 
of clinical target volume (CTV) with margins corresponding to the expected errors.  In 
another word, PTV includes areas larger than the disease sites that will be irradiated.  In 
passively scattered proton therapy (PSPT), both patient set up and range uncertainty 
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have been accounted for during the treatment planning process by use of beam-specific 
hardware such as the lateral expansion of the aperture or block and smearing of the 
compensator (Moyers et al., 2001; Engelsman and Kooy, 2005).  In order to evaluate 
the potential dosimetric error to the target and organs at risk (OAR), the dose-volume 
parameters can be assessed.  However, the uncertainties related to changing in patient 
anatomy are inherently difficult to account for and assess at the time of treatment 
planning process. For example, both inter-fractional and intra-fractional changes in 
patient anatomy during the course of treatment are extremely difficult to predict. During 
the course of radiation treatment, a patient can lose weight leading to  unwanted effects 
on the delivered dose (Albertini et al., 2008). Also, as a patient responds to radiation 
therapy, tumor shape and size, along with other parts of anatomy can change 
significantly and degrade the planned dose distribution in a patient (Wang et al., 2011; 
Hui et al., 2008).  Furthermore, radiotherapy involving either thoracic or 
gastrointestinal sites, breathing motion of the patient is another factor contributing to 
the change in patient anatomy (Engelsman and Kooy, 2005; Kang et al., 2007).  In 
order to mitigate the change in patient anatomy, adaptive re-planning during radiation 
treatment is necessary (Schwarz, 2011; Zhang et al., 2011; Schwartz, 2012). Previously, 
researchers have shown that the change in patient anatomy during the course of 
treatment can significantly degrade planned dose distribution in IMRT (Hurkmans et 
al., 2012; Jensen et al., 2012; Ahn et al., 2011; Nishimura et al., 2011).  It can be 
argued that with the plans that offer more conformal dose distributions, it is more 
difficult to deliver the planned dose without adaptive re-planning because it is harder to 
contain the tumor volume within a smaller volume of irradiation. Proton therapy has 
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been shown to be more conformal than IMRT in certain clinical cases (Lee et al., 2007; 
Chang et al., 2006; Mohan et al., 2010) which could pose a greater risk. Furthermore,  
in proton therapy, beam range is heavily dependent on the tissue density along its beam 
path which makes proton therapy especially error-prone when dealing with changes in 
patient anatomy (Engelsman and Kooy, 2004). The ability of proton therapy to deliver 
dose to a pre-determined depth in a patient and deliver no dose beyond the depth can 
actually cause the beam to either over-shoot or under-shoot depending on the change in 
tissue density (see Figure 3.1). Although IMRT plan can undergo a small perturbation 
in dose distribution as a result of change in anatomy, the magnitude of such change is 
significantly less than that can be caused in proton therapy.  
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Figure 3. 1 Comparison of lung treatment plan and its dose distribution before 
treatment (left column) and in the middle of treatment (right column). The original 
tumor volume has shrunk significantly, and the protons penetrate further into the lower 
density lung volume. The deteriorated dose distribution overshoots further than original 
planned dose thereby increasing dose to both lung and heart tissue (courtesy of Lei 
Dong, M.D. Anderson Cancer Center, Houston, TX). 
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Figure 3.2 shows the perturbation of a dose distribution due to the breathing 
motion of a patient for both IMRT and proton therapy. Different isodose levels remain 
in the same position for IMRT but change significantly for proton therapy primarily due 
to the motion of liver (i.e. indicated with black arrow in the Figure 3.2).  For example, 
35 Gy isodose level (orange line) remains the same for IMRT but it moves 2 cm for 
proton therapy due to the motion of liver.  Delivered dose distribution can be different 
from the planned dose distribution and the magnitude of such differences can be more 
significant for proton therapy than IMRT which challenges many previous studies 
compared the two modalities by only looking at the planned dose distribution and 
ignoring the effect on changing in patient anatomy (Lee et al., 2007; Berman et al., 
2008; Mohan et al., 2010; Krengli et al., 2006; Yeung et al., 2006; Ingram et al., 2007). 
In Chapter 2, we investigated the difference in tumor shrinkage from patients who 
underwent a randomized clinical trial between IMRT and PSPT, and found no 
significant difference between the two modalities in terms of tumor shrinkage.  
Following the result of our previous study, in this chapter our primary goal is to assess 
delivered dose to tumor and other critical structures while accounting for both changing 
in patient anatomy throughout the entire treatment course and breathing motion. To 
date, no previous study has compared the delivered dose between IMRT and PSPT 
which takes into account both inter- and intra-fractional change in anatomy for non-
small cell lung cancer patients.  In multi-fractionated radiotherapy, the delivered dose to 
a patient can be closely approximated by accumulating dose to a patient.  However, due 
to the change in patient anatomy, accumulating dose remains as a challenge.  In this 
chapter we showed a method of explicitly accumulating dose to a patient over different 
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breathing cycles as well as different treatment days by using repeat four-dimensional 
CT (4DCT) and deformable image registration. Although, such accumulated dose is not 
the same as the true delivered dose, it closely resembles the true dose when compared to 
the planned dose. Since the accumulated dose in this work incorporates both breathing 
motion and anatomy change, we referred it as “5D” dose. Based on the 5D dose, we 
assessed the delivered dose to the planned dose for the patients who were treated either 
with IMRT or proton therapy according to the NIH P01 randomized clinical trial 
discussed in Chapter 1.   
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Figure 3.2 Comparison of dose distributions at inhale (right column) and exhale (left 
column) of breathing cycle for IMRT (bottom row) and proton therapy plan (top row). 
The arrow indicates region where a significant change in isodose level is shown for 
proton therapy and not for IMRT. (courtesy of Lei Dong, M.D. Anderson Cancer Center, 
Houston, TX). 
 
 
 
 
 
54 
 
  
3.2 Methods and Materials 
 
An assessment of the 5D dose distribution to a lung cancer patient requires 
repeat 4DCT scans of the patient during the course of radiation therapy to track the 
breathing motion and change in patient anatomy. One 4DCT scan consists of 10 image 
data sets that are 3D images of one patient at different breathing cycle.  The repeated 
4DCT images sets can be aligned with respect to the specific respiratory phase of the 
planning CT images by deformable image registration.  Deformable image registration 
is then used to accumulate dose distributions calculated from different CT images. The 
use of deformable image registration to establish voxel to voxel geo-spatial relationship 
between two different CT image sets for dose accumulation has been reported 
previously (Velec et al., 2009; Lu et al., 2006; Brock et al., 2008; Janssens et al., 2009). 
In this study, we used in-house developed deformable image registration software called 
CT-Assisted Targeting for Radiation Therapy - CATV3.0 that is based on the demon’s 
algorithm (Wang et al., 2005; Gao et al., 2006; Wang et al., 2006).  A pilot study was 
designed to look at a group of 7 patients who represent the most typical patient 
population underwent the P01 randomized clinical trial for non-small cell lung cancer 
including two extreme cases.  Patient number 2 has the largest tumor motion and patient 
number 7 has the largest initial tumor volume. Notice that these seven patients were 
chosen from specific aim I.  Table 3.1 shows individual patient characteristics including 
age, sex, stage, histology, treatment modality, planning primary Gross Tumor Volume 
(GTVp), tumor motion, and tumor location.  One tumor was located in the left upper 
lobe (LUL), two were in the right lower lobe (RLL), and four were in the right upper 
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lobe (RUL).  The range of GTVp volume was between 13 – 622 cc.  For each of these 
patients, physician approved IMRT plan and PSPT plans were designed using Pinnacle3 
(Philips Medical Systems, Andover, MA) and EclipseTM (Varian Medical System, Palo 
Alto, CA) respectively (see Figure B.1-B.14 from Appendix B).  For each patient, both 
IMRT and PSPT plans were created to achieve dose objectives for different critical 
structures and approved for treatment.  The plans were normalized to deliver 74Gy to 
95% of the PTV with no hot spots greater than 110% of the prescription dose for more 
than 2cc volume. The detail description of the dose objectives used to create the 
treatment plans for both modalities was summarized in Table 1.1 of Chapter 1.  
 
Table 3.1 Patient Characteristics used in this study 
 
Patient 
# 
Sex Age 
(y) 
Stage Histology Treatmen
t 
Planning 
GTVp 
(T50) [cc] 
Tumor 
Motion 
[mm] 
Tumor 
Location 
1 M 68 IIIa Squamous cell 
Carcinoma 
PSPT 13 5.5 LUL 
2 M 76 IIIa Adenocarcinoma PSPT 32 17 RLL 
3 F 75 IIIb Adenocarcinoma IMRT 46 4.7 RUL  
4 M 67 IIIa Adenocarcinoma IMRT 63 9 RLL 
5* M 63 III Squamous cell 
Carcinoma 
PSPT 149 3 RUL  
6 F 74 IIIa Carcinoma IMRT 202 4 RUL  
7¥ M 57 IIIb Adenocarcinoma PSPT 622 5.5 RUL  
*Patient 5 had one adaptive replan. 
¥Patient 7 had two adaptive replans. 
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Each of these patients received weekly 4DCT scans during their actual treatment 
course. These 4DCT data sets were backed up to our image archiving system and later 
imported into the Pinnacle and Eclipse treatment planning systems. Our 4DCT image 
sets consisted of 10 respiratory phases (T0 to T90). At all 10 phases, dose distributions 
were recalculated for all available weekly 4DCT data sets using Pinnacle and Eclipse 
treatment planning systems for IMRT and PSPT plans respectively. The number of 
weekly 4DCT sets received by patients ranged from 5 to 8 weekly 4DCT data sets for 
all patients. Therefore, for each patient, between 60 to 90 dose calculations were 
performed for both IMRT plans and PSPT plans including accumulating planned dose 
distribution. After the dose calculations were done, for each weekly 4DCT, the dose 
distributions calculated for the 10 different respiratory phases  were deformed to the 
maximum exhale phase (T50) using the CAT software. The process of acquiring 
deformed vector fields that were later used to map dose started with rigid alignment of 
the two CT images sets based on the bony structures to establish a baseline prior to 
deformable image registration. Once the deformed vector fields were obtained, the 
newly calculated dose points associated with each of these voxels are mapped to the 
T50 phase of the same week except patient number 5 and 6 whose dose points are 
mapped directly to the T50 of planning 4DCT data sets. In order to inspect the result of 
deformable image registration, at least one contour which is typically a gross tumor 
volume (GTV) was visually assessed for any irregularities in contours and in deformed 
vector fields before and after the deformable image registration.  These deformed doses 
from individual phases were summed with equal weight to represent the breathing time-
resolved, 4D dose of the patient for that particular week represented on the T50 phase.  
57 
 
  
Next, the 4D doses calculated on all weekly 4DCT image sets were deformed to the T50 
phase of the planning 4DCT image set.  Again, these deformed doses were summed 
with equal weight. In this way, the 5D dose that are accumulated over all breathing 
phases and all weekly 4DCT image sets were represented as the single dose distribution 
overlaid on the top of the T50 phases of the planning CT for direct comparison with the 
planned dose distribution. Figure 3.3 illustrates the process of accumulating dose in this 
study.  The 5D dose, which is a close approximation of the delivered dose, was 
compared to the planned dose using dose-volume histograms (DVHs). The planning 
parameters such as target coverage and dose limits to critical structures were compared 
to check if any significant deviation occurred. 
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Figure 3.3 Process of dose accumulation. First, to obtain accumulated dose over the 
breathing cycle, dose calculations were performed on all 10 phases of weekly 4DCT 
scans. These dose distributions were mapped onto the T50 phases of CT images set. The 
cumulated dose at T50 of weekly 4DCT was deformed again to the T50 of planning 
4DCT image set. This process was repeated for all available weekly 4DCT image sets. 
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3.3 Results 
The differences between the 5D dose and the planned dose in terms of the dose 
coverage to target volume and dose objectives of the critical structures were compared 
for both IMRT and PSPT plans.  Between 60 to 100 individual dose calculations were 
performed for each patient.   Then, the accumulated dose distributions to T50 phase of 
the planning CT image were compared with the planned dose distribution calculated on 
the T50 phase of the planning CT image.  For every patient, 5D dose distribution was 
visually inspected against the planned dose distribution for any unusual deviation 
introduced by human error while importing or exporting the data.  The original planned 
dose distributions are shown in Appendix B for both IMRT and PSPT plans in 3 
different views (axial, sagittal, and coronal) followed by the dose-volume histogram 
(DVH) comparisons between 5D dose and planned dose for target volume and critical 
structures for all patients.  Below sections show results for target volume and critical 
structures in details. 
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CTV 
Initial target coverage under the planned dose distribution was similar between 
IMRT and PSPT plans for all our patients, with less than 1% average difference of CTV 
V74Gy criteria indicating that our plans for both arms were designed according to our 
target coverage criteria. When comparing the CTV V74Gy of the planned dose 
distribution with the 5D dose distribution, we found that the original CTV V74Gy 
coverage was maintained in 5 out 7 patients for IMRT plans, and 6 out of 7 patients for 
PSPT plans. Patient No. 2 and 7 showed -2% and -7% decreases in CTV V74Gy in 
IMRT plan, respectively. But for PSPT plans, only the patient No. 7 showed -9% 
decreases (See figure 3.4). 
 
Figure 3.4 The difference of CTV receiving 74Gy between 5D and planned dose 
distributions for all patients for both IMRT (blue or left column) and PSPT (red or right 
column) plans.   
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 Lung 
For all dose objectives related to the total lung, (i.e. V5, V10, V20, Mean Lung Dose or 
MLD), we observed that the 5D doses were slightly larger than or equal to the planned 
doses for IMRT plans. Similarly, for PSPT plans the 5D doses were larger for most of 
the patients except for patient No. 7 who showed 47cGy reduction in  MLD. Figure 3.5 
shows the results related to the total lung dose objectives. The largest increase was 
observed for V5 and was 5% for IMRT plans, and 6% for PSPT plans. 
 
 
Figure 3.5 The difference of total lung receiving mean lung dose, 5Gy,  10Gy, and 
20Gy between 5D and planned dose distributions for all patients for both IMRT (blue or 
left column) and PSPT (red or right column) plans.   
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Esophagus 
For the esophagus V55 objective,  1 out of 7 patients showed greater than 3% increases 
for the IMRT plan, while for the PSPT plan, 1 out of 7 patients showed greater than 3% 
increases and patient  NO. 1 showed a -1% decrease (see figure 3.6).  
 
 
Figure 3.6 The difference of esophagus receiving 55Gy between 5D and planned dose 
distributions for all patients for both IMRT (blue or left column) and PSPT (red or right 
column) plans.   
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Heart 
For the heart V45 dose objective, only a slight difference between the planned 
and 5D doses were observed for all patients (within 1% difference) except patient No. 7, 
who showed up to a 3% and 4% difference for IMRT and PSPT plans, respectively. 
Similarly, for the mean heart dose, except for patient No. 7, all differences were less 
than 200cGy (see figure 3.7). 
 
 
Figure 3.7 The difference of heart receiving mean heart dose and 40Gy between 5D 
and planned dose distributions for all patients for both IMRT (blue or left column) 
and PSPT (red or right column) plans.   
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Spinal Cord 
For the maximum spinal cord dose objective, only one out of 7 patients 
indicated that the 5D dose was less than the planned dose for the IMRT plan, while 4 
out of 7 patients indicated that the 5D dose was less than the planned dose for the PSPT 
plan. However, in all cases, the increased maximum cord dose calculated under the 5D 
dose distributions were still below our 50Gy criteria (see figure 3.8). 
 
 
Figure 3.8 The difference of max dose of spinal cord for all patients for both IMRT 
(blue or left column) and PSPT (red or right column) plans.   
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3.4 Discussion 
In this study, we established a method of estimating the 5D dose of both IMRT 
and PSPT plans using weekly 4DCT data sets and deformable image registration.  The 
5D dose closely approximates delivered dose by accumulating dose distributions 
calculated at every respiratory phase of weekly 4DCT data sets to account for both 
patient breathing motion and the change in anatomy during the course of treatment. For 
all 7 patients considered in this study, the 5D dose was very close to the planned dose 
except with patient No. 7. The average difference in CTV 74Gy coverage between 5D 
and planned dose was -1.7% and -1.3% for IMRT and PSPT respectively. For the 
patient No. 7, the difference in CTV 74GY coverage was -7 % and -9 % for IMRT and 
PSPT respectively. It is interesting to note that the patient No. 7 had the largest GTV 
volume at the time of treatment simulation (622 cc) and lost 52% of its initial volume 
over the course treatment. The greater difference in CTV coverage for this patient could 
be attributed to the huge reduction of GTV volume during the course of treatment that 
freed up more lung volume thereby changing tissue density along the beam path.  
During the time of simulation, significant portion of GTV volume and surrounding area 
were considered to be soft tissue. However, during the course of treatment, density 
surrounding the tumor becomes lower than the soft tissue as tumor shrinks thereby 
degrading the planned dose distribution.   
Noticed that in this study, we did not separate patient groups by the modalities 
used for actual treatment because we were interested to find out,  for a selected patient, 
if both IMRT and PSPT plans were given, how the 5D dose as calculated by utilizing 
weekly 4DCT compared to the  planned dose. It should be noted that the weekly 4DCT 
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is taken during a course of treatment that was randomized to either IMRT or proton 
therapy. Therefore, there might be a bias introduced in our hypothetical treatment study: 
using the weekly 4DCT associated with one particular modality to study both arms. But 
from the result of Chapter 2 (Specific Aim I), we showed that there is no significant 
difference in terms of tumor shrinkage between IMRT and proton therapy patients.  
Therefore, we can assume that the tumor shrinkage is the same between the two 
treatment arms for specific aim II. The 5D dose is only an approximation to the true 
delivered dose because we ignore the other types of errors such as patient setup error 
and range error into our calculation. However, in general, these errors are considered 
during the treatment planning process in terms of target margin (i.e. for IMRT plan) or 
by shaping beam-specific hardware such as aperture and compensator (i.e. for PSPT 
plan) and therefore do not significantly degrade the target coverage or plan quality 
when compared to the error caused by anatomical deformation.  However, due to the 
difficulty in predicting anatomical deformation, both breathing motion and anatomy 
change are not usually accounted for during treatment planning process.  Moreover, 
there is no conventional method of estimating dosimetric errors due to anatomy change 
in advance.  Although breathing motion is partially accounted for during treatment 
planning process by incorporating internal target volume (ITV), patient breathing 
pattern can change during the course of treatment.   
 This pilot study was intended to estimate the difference between 5D dose and 
planned dose of both IMRT and PSPT plans but the result of all our 7 patients only 
showed a mean difference of 1% (shown in Table 3.2).  Moreover, if we assumed 
patient No. 7 to be an outlier, then the mean difference between 5D dose and planned 
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dose of both IMRT and PSPT plans is even smaller as shown in Table 3.3.  The mean 
difference has changed from 1.1 to 0.3 for IMRT and 1.0 to -0.3 for PSPT if we exclude 
patient No. 7.  Based on the narrow range of 95% confidence level shown below for 
both IMRT and PSPT, we can conclude that the difference between 5D dose and 
planned dose of both IMRT and PSPT are consistently small.  Similarly, for  the critical 
structures, the difference between the 5D dose and planned dose were in the clinically 
acceptable range for all patients including patient No. 7.  Such small difference between 
the 5D dose and planned dose observed in our study indicates that the anticipated 
concerns of dosimetric errors caused by anatomical change during the course of 
treatment might have been over estimated especially for those patients with small initial 
tumor volume.  The reason for such small difference in terms of CTV coverage can be 
attributed to the generous treatment margins during the treatment planning process.  
Although, the treatment margins are not directly design to account for the anatomical 
change, in our analysis, they are proven to be effective against the change in anatomy as 
well.  However, when it comes to estimate the true 5D dose, we should include patient 
setup errors along with the anatomical deformation that could potentially cause the 
dosimetric difference than what was observed in this study.  The scope of this study was 
limited that it did not incorporate setup errors associated with proton beam range for 
PSPT plans.  A more comprehensive method of computing the 5D dose under the 
influence of both setup and range error is warranted for the future study. 
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Table 3.2 Mean, SD, and CI for both IMRT and PSPT CTV V74 for all 7 patients 
 
Patient No. IMRT CTV V74 PSPT CTV V74 
Planned 5D Planned-5D Planned 5D Planned-5D 
1 100 100 0 99 99 0 
2 100 98 2 100 100 0 
3 98 98 0 97 97 0 
4 100 100 0 98 98 0 
5 100 100 0 97 99 -2 
6 98 98 0 100 100 0 
7 99 93 6 98 89 9 
Mean   1.1   1.0 
STD   2.3   3.6 
95%CI   [-0.95,3.2]   [-2.3,4.3] 
 
Table 3.3 Mean, SD, and CI for both IMRT and PSPT CTV V74 for all 6 patients 
 
Patient No. IMRT CTV V74 PSPT CTV V74 
Planned 5D Planned-5D Planned 5D Planned-5D 
1 100 100 0 99 99 0 
2 100 98 2 100 100 0 
3 98 98 0 97 97 0 
4 100 100 0 98 98 0 
5 100 100 0 97 99 -2 
6 98 98 0 100 100 0 
Mean   0.3   -0.3 
STD   0.8   0.8 
95%CI   [-0.5,1.2]   [-1.2,0.5] 
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3.5 Conclusion 
In this study, we established the method of estimating the 5D dose of both 
IMRT and PSPT plans using weekly 4DCT data sets and deformable image registration.  
In addition, we compared this 5D dose to the original planned dose to assess the effect 
of both breathing motion and the change in patient anatomy over the course of treatment 
on the final dose distribution the patient receives. Furthermore, by applying the same 
technique to both the IMRT and the PSPT therapy plan of an individual patient, we 
compared the sensitivity of the 5D dose distribution to the planned dose between both 
IMRT and PSPT therapy. All of the patients studied in this chapter showed that the 5D 
dose distribution closely follows the planned dose distribution within the limits of initial 
dose objectives. That is, some changes in the 5D dose distributions that were observed 
were still within the limits of our plan criteria. With limited patient numbers studied so 
far, we could not reach a definite conclusion in terms of whether or not PSPT plan is 
more sensitive to the anatomical change.  
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Chapter 4 
Conclusions 
 
4.1 Conclusions of Hypothesis 1 
 
Hypothesis 1: We hypothesized that there is a statistically significant difference 
in tumor shrinkage between lung cancer patients treated with IMRT and those 
treated with PSPT. 
 
 The motivation of our Hypothesis 1 derives from the speculation that proton 
therapy is inherent more sensitive to anatomical change due to the finite range of proton 
beam that is highly dependent on tissue density.  In chapter 2, we investigated the tumor 
shrinkage of 25 Intensity Modulated Radiation Therapy (IMRT) and 20 Passively 
Scattered Proton Therapy (PSPT) patients who were randomly assigned to receive 
either IMRT or PSPT for locally advanced non-small cell lung carcinoma. In both 
groups, 24% (  19%) and 21% (  17 %) of initial primary Gross Tumor Volume 
(GTVp)  were reduced for IMRT and PSPT respectively.  The 95% confidence interval 
for the mean difference in tumor shrinkage between the two arms was [-8%, 14%]. 
According to our statistical test (i.e. Welch’s non-paired t-test) with the null hypothesis 
that the mean tumor shrinkages for both modalities are the same, we obtained p-value = 
0.65. This result suggests that we cannot reject the null hypothesis. Therefore, we 
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concluded that there is no statistical difference in mean tumor shrinkage between IMRT 
and PSPT patients. The clinical interpretation of this result can be that the overall 
therapy responses in terms of tumor shrinkage between the two modalities were similar 
and this is a positive result since our clinically intended goal was to deliver same 
prescription dose to both groups of patients. Although it is true that the proton beam is 
more sensitive to the tissue density change caused by the anatomical variation from 
breathing motion and tumor shrinkage, the original plan design method (i.e. beam 
shaping strategy and treatment margin) is vastly different between the two modalities 
and some of the uncertainties that are more pronounced in proton beam is being taken 
into special account during design of proton radiation therapy planning.  
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4.2 Conclusions of Hypothesis 2 
 
Hypothesis 2: We hypothesized that there is a statistically significant difference 
between planned and 5D dose in both IMRT and PSPT plans of the lung cancer 
patients. 
 
 The motivation of our Hypothesis 2 was similar to that of Hypothesis 1.  In 
chapter 3, we established a method of estimating the 5D dose of both IMRT and PSPT 
plans using weekly 4DCT and the in-house developed deformable image registration 
software, CAT.  Moreover, we performed a pilot study of comparing planned dose to 
5D dose for both modalities using 7 patients selected from the randomized clinical trial.  
Unlike our previous study in chapter two which separates the patients by the chosen 
treatment modality, this study assumed that each patient received both IMRT and PSPT 
treatments at the same time.  This assumption is valid since the conclusion from chapter 
two has showed us that the tumor shrinkage between IMRT and PSPT patients is 
similar.  In order to approximate the 5D dose to a patient, individual dose was re-
calculated on all 10 phases of weekly 4DCT data sets separately and then deformed to 
the T50 (end of exhale) phase of the same week.  Finally, dose distributions from each 
week were all deformed to the T50 phase of the planning 4DCT data sets for direct 
comparison with the planned accumulated dose.  In this study, for all 7 patients, the 
mean difference between the 5D dose and planned dose of both IMRT and PSPT plans 
was only 1% for the target volume. Based on the 95% confidence interval, [-0.95%, 
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3.2%] and [-2.3%, 4.3%] for IMRT and PSPT respectively, we can conclude that the 
difference between 5D dose and planned dose of both IMRT and PSPT are consistently 
small.  However, with small number of patient sample size, we could not reach a 
conclusion if PSPT plan is more sensitive to the anatomical change than IMRT plan. 
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APPENDIX A: 
Table A.1  It represents individual patient versus elapsed treatment days for primary GTV of IMRT patients.  Linear interpolation was 
applied between two consecutive 4DCT weeks in order to interpret the result between them. 
Patient 
no./ 
Days 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
0               1.0                                   
1         1.0     1.0                                   
2 1.0       1.0     1.0     1.0   1.0   1.0 1.0   1.0 1.0             
3 1.0   1.0   1.0     1.0   1.0 1.0 1.0 1.0   1.0 1.0   1.0 1.0     1.0       
4 1.0   1.0   1.0     1.0   1.0 1.0 1.0 1.0   0.9 1.0 1.0 1.0 1.0     1.0       
5 1.0 1.0 1.0 1.0 1.0     1.0   1.0 1.1 1.0 1.0   0.9 1.0 1.0 1.0 0.9     1.0       
6 1.0 1.0 1.0 1.0 1.0   1.0 0.9 1.0 1.0 1.1 1.0 1.0 1.0 0.9 1.0 1.0 1.0 0.9     0.9 1.0     
7 1.0 0.9 0.9 1.0 1.0 1.0 1.0 0.9 1.0 1.0 1.1 1.0 1.0 1.0 0.9 1.0 1.0 1.0 0.9 1.0 1.0 0.9 1.0 1.0   
8 1.0 0.9 0.9 1.0 1.0 1.0 1.0 0.9 1.0 1.0 1.1 0.9 1.0 1.0 0.8 1.0 1.0 1.0 0.9 1.0 1.0 0.9 1.0 1.0 1.0 
9 1.0 0.9 0.9 1.0 1.0 0.9 1.0 0.9 1.0 1.0 1.1 0.9 0.9 1.0 0.8 0.9 1.0 1.0 0.9 1.0 1.0 0.9 1.0 1.0 1.0 
10 1.0 0.8 0.9 0.9 1.0 0.9 1.0 0.9 1.0 1.0 1.1 0.9 0.9 1.0 0.8 0.9 1.0 1.0 0.9 0.9 1.0 0.9 1.0 1.0 1.0 
11 1.0 0.8 0.9 0.9 1.0 0.8 1.0 0.9 1.0 1.0 1.1 0.9 0.9 0.9 0.7 0.9 0.9 1.0 0.8 0.9 0.9 0.9 1.0 0.9 1.0 
12 1.0 0.8 0.9 0.9 1.0 0.8 0.9 0.9 1.0 1.0 1.2 0.9 0.9 0.9 0.7 0.9 0.9 1.0 0.8 0.9 0.9 0.9 1.0 0.9 1.0 
13 1.0 0.7 0.9 0.9 1.0 0.7 0.9 0.9 1.0 1.0 1.2 0.9 0.9 0.9 0.7 0.9 0.9 1.0 0.8 0.9 0.9 0.9 1.0 0.9 1.0 
14 0.9 0.7 0.9 0.9 1.0 0.7 0.9 0.9 1.0 1.0 1.2 0.8 0.9 0.9 0.7 0.9 0.9 1.0 0.8 0.9 0.9 0.9 1.0 0.9 1.0 
15 0.9 0.7 0.9 0.9 1.0 0.7 0.9 0.9 1.0 1.0 1.2 0.8 0.9 0.9 0.6 0.9 0.9 1.0 0.8 0.9 0.9 0.9 1.0 0.9 1.0 
16 0.9 0.7 0.9 0.9 1.0 0.7 0.9 0.9 1.0 1.0 1.2 0.8 0.9 0.9 0.6 0.9 0.9 1.0 0.8 0.8 0.9 0.9 1.0 0.9 1.0 
17 0.9 0.7 0.9 0.9 1.0 0.6 0.9 0.9 1.0 1.0 1.2 0.8 0.9 0.9 0.6 0.9 0.8 1.0 0.7 0.8 0.9 0.9 1.0 0.9 1.0 
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Table A.1 Continued. 
Patient 
no./ 
Days 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
18 0.9 0.7 0.9 0.9 1.0 0.6 0.9 0.9 1.0 1.0 1.1 0.7 0.9 0.9 0.6 0.9 0.8 1.0 0.7 0.8 0.8 0.9 1.0 0.8 1.0 
19 0.9 0.7 0.9 0.9 1.0 0.6 1.0 0.9 1.0 1.0 1.1 0.7 0.9 0.8 0.6 0.9 0.8 1.0 0.7 0.8 0.8 0.9 1.0 0.8 1.0 
20 0.9 0.7 0.9 0.9 1.0 0.6 1.0 0.8 1.0 1.0 1.1 0.7 0.9 0.8 0.5 0.9 0.8 1.0 0.7 0.8 0.8 0.9 1.0 0.8 0.9 
21 0.9 0.7 0.9 0.9 1.0 0.6 1.0 0.8 1.0 1.0 1.1 0.7 0.9 0.8 0.5 0.9 0.8 1.0 0.7 0.8 0.8 0.9 0.9 0.8 0.9 
22 0.9 0.7 0.9 0.9 1.1 0.6 1.0 0.8 1.0 1.0 1.1 0.7 0.9 0.8 0.5 0.9 0.8 1.0 0.7 0.8 0.8 0.9 0.9 0.8 0.9 
23 0.9 0.7 0.9 0.9 1.1 0.6 1.0 0.8 1.1 1.0 1.1 0.6 0.9 0.8 0.5 0.9 0.7 1.0 0.7 0.8 0.8 0.9 0.9 0.8 0.9 
24 0.9 0.7 0.9 0.9 1.1 0.6 1.0 0.8 1.1 1.0 1.1 0.6 0.9 0.8 0.5 0.9 0.7 1.0 0.7 0.7 0.8 0.9 0.9 0.8 0.9 
25 0.9 0.7 0.9 0.9 1.1 0.6 1.0 0.8 1.1 1.0 1.1 0.6 0.9 0.7 0.5 0.9 0.7 1.0 0.7 0.7 0.7 0.9 0.9 0.7 0.9 
26 0.9 0.7 0.9 0.9 1.1 0.6 1.0 0.8 1.1 1.0 1.1 0.6 0.9 0.7 0.5 0.9 0.7 1.0 0.7 0.7 0.7 0.9 0.9 0.7 0.9 
27 0.9 0.7 0.9 0.9 1.1 0.6 1.0 0.8 1.1 1.1 1.1 0.6 0.9 0.7 0.4 0.9 0.7 1.0 0.7 0.7 0.7 0.9 0.9 0.7 0.9 
28 0.9 0.7 0.9 0.9 1.1 0.6 1.0 0.8 1.1 1.1 1.0 0.6 0.9 0.7 0.4 0.9 0.7 1.0 0.7 0.7 0.7 0.9 0.9 0.7 0.9 
29 0.9 0.6 0.8 0.9 1.1 0.6 1.0 0.8 1.1 1.1 1.0 0.7 0.9 0.7 0.4 0.9 0.7 1.0 0.7 0.7 0.7 0.9 0.9 0.7 0.9 
30 0.9 0.6 0.8 0.9 1.1 0.6 1.0 0.8 1.0 1.1 1.0 0.7 0.9 0.7 0.4 0.9 0.6 1.0 0.7 0.7 0.7 0.9 0.9 0.7 0.9 
31 0.9 0.6 0.8 0.9 1.1 0.6 1.0 0.8 1.0 1.1 1.0 0.7 0.9 0.7 0.4 0.9 0.6 1.0 0.7 0.6 0.6 0.9 0.8 0.6 0.9 
32 0.9 0.6 0.8 0.9 1.1 0.6 0.9 0.8 1.0 1.1 1.0 0.7 0.9 0.7 0.4 0.9 0.6 1.0 0.6 0.6 0.6 0.9 0.8 0.6 0.9 
33 0.9 0.6 0.8 0.9 1.1 0.5 0.9 0.8 1.0 1.1 1.0 0.7 0.9 0.7 0.4 0.9 0.6 1.0 0.6 0.6 0.6 0.9 0.8 0.6 0.9 
34 0.9 0.6 0.8 0.9 1.1 0.5 0.9 0.8 1.0 1.1 1.0 0.7 0.9 0.7 0.4 0.9 0.6 1.0 0.6 0.6 0.6 0.9 0.8 0.6 0.9 
35 0.9 0.6 0.8 0.9 1.1 0.5 0.9 0.8 1.0 1.1 1.0 0.7 0.9 0.6 0.4 0.9 0.6 1.0 0.6 0.6 0.6 0.9 0.8 0.6 0.9 
36 0.9 0.6 0.9 0.9 1.1 0.5 0.9 0.8 1.0 1.1 1.0 0.7 0.9 0.6 0.4 0.8 0.6 1.0 0.6 0.6 0.6 0.9 0.8 0.6 0.9 
37 0.9 0.6 0.9 0.8 1.1 0.5 0.9 0.8 1.0 1.1 1.0 0.8 0.9 0.6 0.4 0.8 0.6 1.0 0.6 0.6 0.6 0.9 0.8 0.6 0.9 
38 0.9 0.6 0.9 0.8 1.1 0.5 0.9 0.8 1.0 1.1 1.0 0.8 0.9 0.6 0.4 0.8 0.6   0.6 0.6 0.5 0.9 0.8 0.6 0.9 
39 0.9 0.6 0.9 0.8 1.1 0.5 0.9 0.8 1.0 1.1 1.0 0.8 0.9 0.6 0.4 0.8 0.6   0.6 0.6 0.5 0.9 0.8 0.6 0.9 
40 0.9 0.6 0.8 0.8 1.0 0.5 0.9 0.8 1.0 1.0 1.0 0.7 0.9 0.6 0.4 0.8 0.6   0.6 0.6 0.5 0.9 0.8 0.6 0.9 
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Table A.1 Continued. 
 
Patient 
no./ 
Days 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
41 0.9 0.6 0.8 0.8 1.0 0.5 0.9 0.8 1.0 1.0 1.0 0.7 0.9 0.6 0.4 0.8 0.6   0.6 0.6 0.5 0.9 0.8 0.6 0.9 
42 0.9 0.6 0.8 0.8 1.0 0.5 0.9 0.8 1.0 1.0 1.0 0.7 0.9 0.6 0.4 0.8 0.6   0.6 0.6 0.5 0.9 0.8 0.6 0.9 
43 0.9 0.6 0.8 0.8 1.0 0.5 0.9 0.8 1.0 1.0 1.0 0.7 0.9 0.6 0.4 0.8 0.6   0.6 0.6 0.5 0.9 0.8 0.6 0.9 
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Table A.2  It represents individual patient versus elapsed treatment days for primary GTV of PSPT patients.  Linear interpolation was 
applied between two consecutive treatments in order to interpret the result between them. 
Patient 
no./ Days 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
0                                         
1           1.0     1.0 1.0                 1.0   
2   1.0   1.0 1.0 1.0 1.0   1.0 1.0 1.0 1.0     1.0 1.0 1.0   1.0   
3   1.0   1.0 1.0 1.0 1.0   1.0 1.0 1.0 1.0   1.0 1.0 1.0 1.0 1.0 1.0 1.0 
4 1.0 1.0   1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0   1.0 1.0 1.0 1.0 1.0 1.0 1.0 
5 1.0 1.0   1.0 1.0 1.0 1.0 1.0 0.9 1.0 1.0 1.0   1.0 1.0 1.0 1.0 1.0 1.0 1.0 
6 1.0 1.0   1.0 1.0 1.0 1.0 1.0 0.9 1.0 1.0 1.0   0.9 1.0 0.9 1.0 1.0 1.1 1.0 
7 1.0 1.0 1.0 1.0 1.0 1.0 1.0 0.9 1.0 1.0 1.0   0.9 1.0 0.9 1.1 1.0 1.3 0.9 0.9 
8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 0.9 1.0 1.1 1.0 1.0 0.9 1.0 0.9 1.1 1.0 1.2 0.9 0.9 
9 1.1 1.0 1.0 1.0 1.0 1.1 1.0 0.9 1.0 1.1 1.0 1.0 0.9 1.0 0.9 1.1 1.0 1.2 0.9 0.9 
10 1.1 1.0 1.0 1.0 1.0 1.1 1.0 0.9 1.0 1.0 0.9 1.0 0.9 1.0 0.9 1.1 1.0 1.2 0.9 0.9 
11 1.1 0.9 1.0 1.0 1.0 1.0 1.0 0.9 1.0 1.0 0.9 1.0 0.9 1.0 0.9 1.1 1.0 1.1 0.9 0.8 
12 1.1 0.9 1.0 1.0 1.0 1.0 1.0 0.9 1.0 1.0 0.9 1.0 0.9 1.0 0.9 1.1 1.0 1.1 0.9 0.8 
13 1.1 0.9 1.0 0.9 1.0 1.0 1.0 0.8 1.0 1.0 0.9 1.0 0.9 1.0 0.9 1.1 1.0 1.1 0.8 0.8 
14 1.1 0.9 1.0 0.9 0.9 1.0 1.0 0.8 1.0 0.9 0.9 1.0 0.9 1.0 0.9 1.1 0.9 1.0 0.8 0.7 
15 1.0 0.9 1.0 0.9 0.9 1.0 0.9 0.8 1.0 0.9 0.9 1.0 0.9 1.0 0.9 1.1 0.9 1.0 0.8 0.7 
16 1.0 0.9 1.0 0.9 0.9 1.0 0.9 0.8 1.0 0.9 0.9 1.0 0.9 0.9 0.9 1.1 0.9 1.0 0.8 0.7 
17 1.0 0.9 1.0 0.9 0.9 1.0 0.9 0.8 1.0 0.9 0.9 1.0 0.9 0.9 0.9 1.1 0.9 1.0 0.8 0.7 
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Table A.2 Continued. 
Patient 
no./ 
Days 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
18 1.0 0.9 1.0 0.9 0.9 1.0 0.9 0.8 0.9 0.9 0.9 1.0 0.9 0.9 0.9 1.1 0.9 1.0 0.8 0.6 
19 1.0 0.9 1.0 0.9 0.8 1.0 0.9 0.8 0.9 0.9 0.9 1.0 0.9 0.9 0.9 1.0 0.9 1.0 0.8 0.6 
20 1.0 0.9 1.0 0.9 0.8 1.0 0.9 0.8 0.9 0.9 0.9 1.0 0.9 0.9 0.8 1.0 0.9 1.0 0.8 0.6 
21 1.0 0.9 1.1 0.9 0.8 1.0 0.9 0.8 0.9 0.9 0.9 1.0 0.9 0.9 0.8 1.0 1.0 1.0 0.8 0.6 
22 1.0 0.9 1.1 0.9 0.8 1.0 0.9 0.8 0.9 0.9 0.9 1.0 1.0 0.9 0.8 1.0 1.0 1.0 0.8 0.5 
23 1.0 0.9 1.1 0.8 0.8 1.0 0.9 0.8 0.9 0.9 0.9 1.0 1.0 0.9 0.8 1.0 1.0 1.0 0.8 0.5 
24 1.0 0.9 1.1 0.8 0.7 1.0 0.9 0.8 0.9 0.9 0.9 1.0 1.0 0.9 0.8 1.0 0.9 1.0 0.8 0.5 
25 1.0 0.9 1.1 0.8 0.7 1.0 0.9 0.8 0.9 0.9 0.9 1.0 0.9 0.9 0.8 1.0 0.9 1.0 0.8 0.5 
26 1.0 0.9 1.1 0.8 0.7 0.9 0.9 0.8 0.9 0.9 0.9 1.0 0.9 0.9 0.8 1.0 0.9 0.9 0.8 0.5 
27 1.0 0.9 1.1 0.7 0.7 0.9 0.9 0.8 0.9 0.9 0.9 1.0 0.9 0.9 0.8 1.0 0.9 0.9 0.8 0.5 
28 1.0 0.9 1.1 0.7 0.7 0.9 0.9 0.8 0.9 0.9 0.9 1.0 0.9 0.9 0.7 1.0 0.9 0.9 0.8 0.5 
29 1.0 0.9 1.1 0.7 0.7 0.9 0.9 0.8 0.9 0.8 0.9 1.0 0.9 0.9 0.7 1.0 0.9 0.9 0.8 0.4 
30 1.0 0.9 1.1 0.7 0.7 0.9 0.9 0.8 0.9 0.8 0.9 1.0 0.9 1.0 0.7 1.0 0.9 0.9 0.8 0.4 
31 1.0 0.9 1.1 0.7 0.7 0.9 0.8 0.8 0.9 0.8 0.9 1.0 0.9 0.9 0.7 1.0 0.9 0.9 0.7 0.4 
32 1.0 0.8 1.1 0.7 0.7 0.9 0.8 0.8 0.9 0.8 0.9 1.0 0.9 0.9 0.7 1.0 0.9 0.9 0.7 0.4 
33 1.0 0.8 1.1 0.7 0.7 0.9 0.8 0.8 0.9 0.8 0.9 1.0 0.8 0.9 0.7 1.0 0.9 0.8 0.7 0.4 
34 1.0 0.8 1.1 0.7 0.7 0.8 0.8 0.8 0.9 0.8 0.9 1.0 0.8 0.9 0.8 1.0 0.8 0.8 0.7 0.4 
35 1.0 0.8 1.1 0.7 0.7 0.8 0.8 0.8 0.9 0.8 0.9 1.0 0.8 0.9 0.8 1.0 0.8 0.8 0.7 0.4 
36 1.0   1.0 0.6 0.7 0.8 0.8 0.8 0.9 0.8 0.9 1.0 0.8 0.9 0.8 1.1 0.8 0.8 0.7 0.4 
37 1.0   1.0 0.6 0.7 0.8 0.8 0.8 0.9 0.8 0.9 1.0 0.8 0.9 0.8 1.1 0.8 0.8 0.7 0.4 
38 1.0   1.0 0.6 0.7 0.8 0.8 0.8 0.9 0.8 0.9 1.0 0.8 0.9 0.8 1.1 0.8 0.8 0.7 0.4 
40 1.0   1.0 0.6 0.7 0.8 0.8 0.8 0.9 0.7 0.9 1.0 0.8 0.9 0.8 1.1 0.8 0.8 0.7 0.4 
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Table A.2 Continued. 
 
Patient 
no./ 
Days 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
41 1.0   1.0 0.6 0.7 0.9 0.8 0.8 0.9 0.7 0.9 1.0 0.8 0.9 0.8 1.1 0.8 0.8 0.7 0.4 
42 1.0   1.0 0.6 0.7 0.9 0.8 0.9 0.9 0.7 0.9 1.0 0.8 0.9 0.8 1.1 0.8 0.8 0.7 0.4 
43 1.0   1.0 0.6 0.7 0.9 0.8 0.9 0.9 0.7 0.9 1.0 0.7 0.9 0.8 1.1 0.8 0.8 0.7 0.4 
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APPENDIX B: 
 
Figure B.1   Patient 1’s clinical IMRT plan with GTVp in red and original isodose lines 
 
 
Figure B.2   Patient 2’s clinical IMRT plan with GTVp in red and original isodose lines 
 
 
Figure B.3   Patient 1’s clinical IMRT plan with GTVp in red and original isodose lines 
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Figure B.4   Patient 4’s clinical IMRT plan with GTVp in red and original isodose lines 
 
 
Figure B.5   Patient 5’s clinical IMRT plan with GTVp in red and original isodose lines 
 
 
Figure B.6  Patient 6’s clinical IMRT plan with GTVp in red and original isodose lines 
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Figure B.7   Patient 7’s clinical IMRT plan with GTVp in red and original isodose lines 
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Figure B.8   Patient 1’s clinical PSPT plan with GTVp in red and original isodose lines 
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Figure B.9   Patient 2’s clinical PSPT plan with GTVp in red and original isodose lines 
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Figure B.10   Patient 3’s clinical PSPT plan with GTVp in red and original isodose lines 
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Figure B.11   Patient 4’s clinical PSPT plan with GTVp in red and original isodose lines 
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Figure B.12   Patient 5’s clinical PSPT plan with GTVp in red and original isodose lines 
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Figure B.13   Patient 6’s clinical PSPT plan with GTVp in red and original isodose lines 
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Figure B.14   Patient 7’s clinical PSPT plan with GTVp in red and original isodose lines 
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Figure B. 15 Patient 1 DVH for IMRT plan 
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Figure B.16 Patient 1 DVH for PSPT plan 
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Figure B.17 Patient 2 DVH for IMRT plan 
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Figure B.18 Patient 2 DVH for PSPT plan 
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Figure B.19 Patient 3 DVH for IMRT plan 
Planned=Solid 
5D=Dashed 
95 
 
  
 
Figure B.20 Patient 3 DVH for PSPT plan 
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Figure B.21 Patient 4 DVH for IMRT plan 
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Figure B.22 Patient 4 DVH for PSPT plan 
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Figure B.23 Patient 5 DVH for IMRT plan 
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Figure B.24 Patient 5 DVH for PSPT plan 
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Figure B.25 Patient 6 DVH for IMRT plan 
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Figure B.26 Patient 6 DVH for PSPT plan 
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Figure B.27 Patient 7 DVH for IMRT plan 
Planned=Solid 
5D=Dashed 
103 
 
  
 
Figure B.28 Patient No. 7 DVH for PSPT plan 
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Table B.1 CTV V74 for each patient’s IMRT plan  
Patient No. V74 (Planned) V74 (Delivered) %V diff (Delivered - Planned) 
1 100 100 0 
2 100 98 -2 
3 98 98 0 
4 100 100 0 
5 100 100 0 
6 98 98 0 
7 99 93 -7 
 
Table B.2 CTV V74 for each patient’s PSPT plan  
Patient No. V74 (Planned) V74 (Delivered) %V diff (Delivered - Planned) 
1 99 99 0 
2 100 100 0 
3 97 97 0 
4 98 98 0 
5 97 99 2 
6 100 100 0 
7 98 89 -9 
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Table B.3 Total Lung V5 for each patient’s IMRT plan 
Patient No. V5 (Planned) V5 (Delivered) %V diff (Delivered - Planned) 
1 61 62 1 
2 35 38 3 
3 43 46 3 
4 50 51 1 
5 58 59 1 
6 58 62 3 
7 51 56 5 
 
Table B.4 Total Lung V10 for each patient’s IMRT plan 
Patient No. V10 (Planned) V10 (Delivered) %V diff (Delivered - Planned) 
1 45 45 1 
2 23 25 2 
3 31 33 3 
4 39 40 1 
5 43 44 1 
6 43 46 3 
7 36 40 4 
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Table B.5 Total Lung V20 for each patient’s IMRT plan 
Patient No. V20 (Planned) V20 (Delivered) %V diff (Delivered - Planned) 
1 26 26 0 
2 17 18 1 
3 23 25 2 
4 31 32 1 
5 31 32 1 
6 32 35 2 
7 22 24 2 
 
Table B.6 Total Lung Mean Lung Dose for each patient’s IMRT plan 
Patient No. Mean Lung Dose 
(Planned) 
Mean Lung Dose   
(Delivered) 
MLD diff  
(Delivered - Planned) 
[cGy] 
1 1675 1694 19 
2 1161 1213 52 
3 1462 1583 121 
4 2036 2096 61 
5 2097 2170 74 
6 2056 2230 173 
7 1528 1585 57 
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Table B.7 Total Lung V5 for each patient’s PSPT plan 
Patient No. V5 (Planned) V5 (Delivered) %V diff (Delivered - Planned) 
1 43 49 6 
2 21 22 1 
3 43 47 4 
4 45 46 1 
5 37 40 4 
6 53 56 3 
7 36 42 6 
 
Table B.8 Total Lung V10 for each patient’s PSPT plan 
Patient No. V10 (Planned) V10 (Delivered) %V diff (Delivered - Planned) 
1 38 42 4 
2 19 20 1 
3 39 42 3 
4 42 43 1 
5 34 36 2 
6 49 53 3 
7 30 31 2 
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Table B.9 Total Lung V20 for each patient’s PSPT plan 
Patient No. V20 (Planned) V20 (Delivered) %V diff (Delivered - Planned) 
1 31 33 2 
2 18 18 0 
3 30 33 3 
4 39 39 0 
5 29 31 1 
6 43 48 4 
7 22 22 0 
 
Table B.10 Total Lung Mean Lung Dose for each patient’s PSPT plan 
Patient No. Mean Lung Dose  
(Planned) 
Mean Lung Dose 
 (Delivered) 
MLD diff  
(Delivered - Planned) 
[cGy] 
1 1604 1682 78 
2 1083 1092 9 
3 1664 1804 140 
4 2002 2034 32 
5 1721 1827 106 
6 2408 2693 285 
7 1329 1282 -47 
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Table B.11 Esophagus V55 for each patient’s IMRT plan 
Patient No. V55 (Planned) V55 (Delivered) %V diff (Delivered - Planned) 
1 26 26 0 
2 0 0 0 
3 33 37 3 
4 35 36 1 
5 13 13 0 
6 36 37 0 
7 43 43 0 
 
Table B.12 Esophagus V55 for each patient’s PSPT plan 
Patient No. V65 (Planned) V65 (Delivered) %V diff (Delivered - Planned) 
1 25 24 -1 
2 0 0 0 
3 18 22 3 
4 27 28 1 
5 5 5 0 
6 28 29 1 
7 32 29 -3 
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Table B.13 Heart V45 for each patient’s IMRT plan 
Patient No. V45 (planned) V45 (Delivered) %V diff (Delivered - Planned) 
1 1 2 1 
2 0 0 0 
3 0 0 0 
4 22 21 -1 
5 7 8 1 
6 19 19 -1 
7 2 6 4 
 
Table B.14 Heart V45 for each patient’s PSPT plan 
Patient No. V45 (planned) V45 (Delivered) %V diff (Delivered - Planned) 
1 1 1 0 
2 0 0 0 
3 0 1 0 
4 4 4 1 
5 8 9 1 
6 20 20 0 
7 4 7 3 
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Table B.15 Mean Heart Dose for each patient’s IMRT plan 
Patient 
No. 
Mean Heart Dose 
(planned) 
Mean Heart Dose 
(Delivered) 
MHD diff  
(Delivered-Planned) 
[cGy] 
1 779 854 75 
2 1468 1442 -25 
3 98 103 6 
4 2151 2125 -26 
5 1155 1277 122 
6 1810 1802 -8 
7 807 1290 483 
 
Table B.16 Mean Heart Dose for each patient’s PSPT plan 
Patient 
No. 
Mean Heart Dose 
(planned) 
Mean Heart 
Dose (Delivered) 
MHD diff  
(Delivered-Planned) 
[cGy] 
1 187 358 171 
2 88 68 -20 
3 188 279 91 
4 595 767 172 
5 746 873 127 
6 1787 1743 -44 
7 500 869 370 
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Table B.17  Max Spinal Cord Dose for each patient’s IMRT plan 
Patient 
No. 
Max Cord Dose 
(Planned) 
Max Cord Dose 
(Delivered) 
MCD diff  
(Delivered-Planned) 
[cGy] 
1 4406 4516 110 
2 3010 2832 -178 
3 4202 4595 393 
4 4852 5026 174 
5 4648 4665 17 
6 4344 4464 120 
7 4536 4677 141 
 
Table B.18  Max Spinal Cord Dose for each patient’s PSPT plan 
Patient 
No. 
Max Cord Dose 
(Planned) 
Max Cord Dose 
(Delivered) 
MCD diff  
(Delivered-Planned) 
[cGy] 
1 4239 4069 -169 
2 1542 2733 1191 
3 4476 4483 7 
4 3870 3868 -2 
5 2657 3306 649 
6 4929 4841 -88 
7 5269 4486 -783 
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